[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1331
1. Navas Cañete A, Olcoz Monreal FJ, García Laborda E, Pérez Aznar JM: [Pseudoangiomatous stromal hyperplasia: magnetic resonance findings in two cases]. Radiologia; 2007 Jul-Aug;49(4):275-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hiperplasia pseudoangiomatosa estromal: hallazgos en resonancia magnética de dos casos.
  • Pseudoangiomatous stromal hyperplasia (PASH) is a benign breast tumor of uncertain etiology, although marked hormonal influence clearly plays a role in this disease.
  • The differential diagnosis is important because this is an uncommon lesion that can simulate malignant lesions both at clinical and radiological examination, and even the histological results can be confusing.
  • [MeSH-major] Breast / pathology. Breast Diseases / diagnosis. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Pseudoangiomatous stromal hyperplasia.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594891.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Ding GP, Ye CS, Liu MF, Zhen LF, Liao JJ: [Relationship between D2-40-labeled lymphatic vessel invasion and lymph node metastasis of breast cancer]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Oct;30(10):2301-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between D2-40-labeled lymphatic vessel invasion and lymph node metastasis of breast cancer].
  • OBJECTIVE: To investigate the feasibility of D2-40 labeling for detecting lymphatic vessels in breast cancer tissues and the clinicopathological implications of lymphatic vessel invasion (LVI).
  • METHODS: Immunohistochemistry was used to detect the expression of D2-40 and lymphatic invasion in 72 cases of breast cancer and 15 benign breast tumor tissues, and their correlations to the clinicopathological factors were analyzed.
  • RESULTS: The positivity rate of LVI was 69.4% in breast cancer tissue.
  • CONCLUSION: D2-40 can specially and reliably mark the lymphatic vessels in breast cancer tissues.
  • [MeSH-major] Antibodies, Monoclonal. Breast Neoplasms / diagnosis. Immunohistochemistry / methods. Lymphatic Vessels / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20965831.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


3. Feng R, Liu X, Guo Z, Li J: Purification and characterization of 66-kDa glycoprotein from human breast carcinoma. Cancer Sci; 2007 Sep;98(9):1344-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purification and characterization of 66-kDa glycoprotein from human breast carcinoma.
  • We extracted a 66-kDa glycoprotein (GP-1D8) from breast invasive ductal carcinoma tissues.
  • Immunocytochemical and immunohistochemical analysis revealed strong expression of GP-1D8 protein in the cytoplasm of MCF-7 cells and different types of breast carcinoma tissues, but GP-1D8 is absent in normal breast and benign breast tumor tissues.
  • This is the first time human breast carcinoma tissues and MCF-7 cells have been shown to express a 66-kDa glycoprotein similar to human albumin precursor.
  • [MeSH-major] Biomarkers, Tumor / isolation & purification. Breast Neoplasms / chemistry. Carcinoma, Ductal, Breast / chemistry. Glycoproteins / isolation & purification. Neoplasm Proteins / isolation & purification
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line, Tumor. Female. Humans. Mice. Mice, Inbred BALB C. Molecular Sequence Data. Peptide Fragments / chemistry. Protein Precursors / chemistry. Serum Albumin / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640306.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / Serum Albumin
  •  go-up   go-down


Advertisement
4. Fujita T, Hayashi K, Katanoda K, Matsumura Y, Lee JS, Takagi H, Suzuki S, Mizunuma H, Aso T: Prevalence of diseases and statistical power of the Japan Nurses' Health Study. Ind Health; 2007 Oct;45(5):687-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For all diseases except ovarian cancer, the prevalence of a past diagnosis increased markedly with age, and incidence rates could be predicted based on the degree of increase in prevalence between two adjacent 5-yr age groups.
  • The predicted incidence rate for uterine myoma, hypercholesterolemia, and hypertension was > or =3.0 (per 1,000 women, per year), while the rate of thyroid disease, hepatitis, gallstone disease, and benign breast tumor was predicted to be > or =1.0.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057812.001).
  • [ISSN] 0019-8366
  • [Journal-full-title] Industrial health
  • [ISO-abbreviation] Ind Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


5. Ying MG, Chen Q, Ye YB, Chen HJ, Chen X, Zheng HY, Wu F: [Application of serum proteomic mass spectrum analysis in breast cancer]. Zhonghua Zhong Liu Za Zhi; 2010 Sep;32(9):698-702
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of serum proteomic mass spectrum analysis in breast cancer].
  • OBJECTIVE: To analyze the characteristics of serum proteins mass spectra in healthy controls, benign breast tumors, and CA15-3 negative or CA15-3 positive breast cancer patients by surface enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF-MS).
  • METHODS: Tissue samples of 113 cases of breast cancer (93 case of CA15-3 negative, 20 case of CA15-3 positive), 103 cases of benign breast tumor and 92 cases of healthy controls were examined and analyzed by SELDI and protein chip (CM10) techniques.
  • RESULTS: Twelve significantly different protein peaks were found in serum samples between breast cancer patients and healthy controls.
  • Eleven significantly different peaks were found between benign breast tumor patients and healthy controls.
  • By combined analysis of those three different protein mass spectra, the peak 15 952 was found to be significantly different between breast cancer group and healthy controls, and the peak 7985 was significantly different among breast cancer group, benign breast tumor group and health controls.
  • The blind test with the differential proteins for the serum samples of 93 cases of CA15-3 negative breast cancer and 36 cases of benign breast tumors showed that the sensitivity was 80.6% and specificity was 91.7%.
  • The blind test in 20 cases of CA15-3 positive breast cancer and 36 cases of benign breast tumors showed that the sensitivity was 75.0% and specificity was 91.7%.
  • Four significantly different protein peaks were found between the benign breast tumor patients and CA15-3 negative breast cancer patients.
  • CONCLUSION: Significantly different protein peaks can be screened out in breast cancer, benign breast tumor patients and healthy controls by SELDI-TOF-MS analysis.
  • [MeSH-major] Blood Proteins / metabolism. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroadenoma / diagnosis. Proteomics / methods
  • [MeSH-minor] Adenoma / blood. Adenoma / diagnosis. Adenoma / metabolism. Adult. Aged. Biomarkers, Tumor / blood. Case-Control Studies. Female. Humans. Middle Aged. Mucin-1 / metabolism. Protein Array Analysis. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122387.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Mucin-1
  •  go-up   go-down


6. Kijima Y, Umekita Y, Yoshinaka H, Taguchi S, Owaki T, Funasako Y, Sakamoto A, Yoshida H, Aikou T: Stromal sarcoma with features of giant cell malignant fibrous histiocytoma. Breast Cancer; 2007;14(2):239-44
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of primary giant cell malignant fibrous histiocytoma (GCMFH) of the breast.
  • A 56-year-old Japanese woman presented with a firm mass in the right breast.
  • Mammography and ultrasonography revealed a well-circumscribed and lobulated mass in the upper outer quadrant of the right breast, indicative of a benign breast tumor or mucinous carcinoma.
  • Magnetic resonance imaging revealed a restricted breast tumor without intraductal spread.
  • Breast-conserving surgery with axillary lymph nodes dissection was performed.
  • Histological examination showed primary GCMFH of the breast.
  • No metastases were identified in any of the 15 left axillary lymph nodes resected and surgical margins were free from tumor cells.
  • The tumor was negative for both estrogen and progesterone receptor.
  • To our knowledge, only 30 cases of primary MFH of the breast have been reported in the literature.
  • [MeSH-major] Breast Neoplasms / pathology. Giant Cell Tumors / pathology. Histiocytoma, Malignant Fibrous / pathology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17485912.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 28
  •  go-up   go-down


7. Ławicki S, Szmitkowski M, Wojtukiewicz M: The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. Clin Chim Acta; 2006 Sep;371(1-2):112-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
  • BACKGROUND: In the present study, we investigated the plasma levels of M-CSF and commonly accepted tumor marker (antigen CA 15-3) in breast cancer patients in relation to the group with benign breast tumor and to the healthy controls.
  • Additionally, we compared the plasma level of M-CSF with the tumor stage of breast cancer and defined the diagnostic criteria: sensitivity, specificity, the positive and the negative predictive values.
  • METHODS: M-CSF and CA 15-3 were measured in 80 patients with breast cancer, 17 patients with benign breast tumor and in 30 healthy subjects.
  • RESULTS: There were statistically significant differences in the levels of circulating M-CSF and CA 15-3 in the breast cancer patients comparing to the group with benign breast tumor and to the control group.
  • The levels of M-CSF and CA 15-3 were also significantly higher in patients with more advanced tumor stage.
  • Statistically significant positive correlation was observed between the M-CSF and CA 15-3 levels.
  • The M-CSF and CA 15-3 diagnostic specificities were 95%.
  • We observed a higher range of the diagnostic sensitivity of M-CSF in more advanced breast tumor stage.
  • The M-CSF area under the ROC curve was larger (0.801) than the ROC area of CA 15-3 (0.785).
  • CONCLUSIONS: These results suggest that M-CSF is the good candidate for a breast cancer tumor marker.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Macrophage Colony-Stimulating Factor / blood. Mucin-1 / blood
  • [MeSH-minor] Adult. Aged. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. ROC Curve. Reagent Kits, Diagnostic. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631152.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Reagent Kits, Diagnostic; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


8. Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R: Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res; 2005 May 1;65(9):3796-805
Xenbase. Xenbase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas.
  • A suppression subtractive cDNA library representing mRNAs expressed at a higher level in the malignant human breast cancer cell line, MCF-7, relative to a benign breast tumor-derived cell line, Huma 123, contained a cDNA, M36, which was expressed in estrogen receptor alpha (ERalpha)-positive breast carcinoma cell lines but not in cell lines from normal/benign/ERalpha-negative malignant breast lesions.
  • Screening of breast tumor specimens using reverse transcription-PCR and immunocytochemistry with affinity-purified anti-AGR2 antibodies showed that the presence of AGR2 mRNA and protein were both statistically significantly associated with ERalpha-positive carcinomas (P = 0.007, Fisher's exact test) and with malignancy (P < or = 0.025).
  • When an expression vector for AGR2 cDNA was introduced into benign nonmetastatic rat mammary tumor cells, and three separate clones and two pools of cells were transferred to the mammary glands of syngeneic hosts, there were no consistent differences in the mean latent periods of tumor formation.
  • However, metastases occurred in the lungs of animals receiving the AGR2 transfectants in 77% to 92% of animals with primary tumors (P = 0.0001) compared with no metastases in the control groups.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Animals. Cell Adhesion / physiology. Cell Line, Tumor. DNA, Complementary / genetics. DNA, Neoplasm / genetics. Humans. Immunohistochemistry. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Rats. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867376.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


9. Román-Díaz J, Alayón-Laguer D, Fernández Nelson M, Luis B, Caceres-Perkins W, Conde-Sterling D: Rare benign breast tumor. Bol Asoc Med P R; 2010 Apr-Jun;102(2):50-2
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare benign breast tumor.
  • We report the case of a female patient with an incidental finding at routine mammography evaluation which consisted of a benign spindle cell tumor, namely Breast Myofibroblastoma.
  • It is important to recognize the benign nature of this neoplasm to prevent extensive mutilating surgical procedures.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasms, Muscle Tissue / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20939206.001).
  • [ISSN] 0004-4849
  • [Journal-full-title] Boletín de la Asociación Médica de Puerto Rico
  • [ISO-abbreviation] Bol Asoc Med P R
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


10. Iwamitsu Y, Shimoda K, Abe H, Tani T, Okawa M, Buck R: Anxiety, emotional suppression, and psychological distress before and after breast cancer diagnosis. Psychosomatics; 2005 Jan-Feb;46(1):19-24
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anxiety, emotional suppression, and psychological distress before and after breast cancer diagnosis.
  • The authors examined the influence of anxiety and emotional suppression on psychological distress in 21 patients with breast cancer and 72 patients with benign breast tumor.
  • The patients with breast cancer who suppressed emotion and had chronically high levels of anxiety felt higher levels of emotional distress both before and after the diagnosis.
  • Such patients need psychological interventions, including encouragement to express and communicate their emotions, immediately after disclosure of the diagnosis to help maintain psychological adjustment in the face of the disease.
  • [MeSH-major] Anxiety / psychology. Breast Neoplasms / psychology. Emotions. Repression, Psychology. Sick Role
  • [MeSH-minor] Adaptation, Psychological. Adult. Affective Symptoms / diagnosis. Affective Symptoms / psychology. Aged. Breast Cyst / psychology. Female. Humans. Internal-External Control. Manifest Anxiety Scale. Middle Aged. Patient Care Team. Personality Inventory

  • Genetic Alliance. consumer health - Anxiety.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15765817.001).
  • [ISSN] 0033-3182
  • [Journal-full-title] Psychosomatics
  • [ISO-abbreviation] Psychosomatics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Ben Hassouna J, Damak T, Ben Slama A, Chargui R, Ben Dhiab T, Khomsi F, Gamoud A, Boussen H, Rahal K: Breast carcinoma arising within fibroadenomas. Report of four observations. Tunis Med; 2007 Oct;85(10):891-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinoma arising within fibroadenomas. Report of four observations.
  • BACKGROUND: Fibroadenoma is a frequent benign breast tumor affecting young woman.
  • AIM: The purpose of this study was to evaluate the outcome of patients with breast carcinoma arising within adenofibroma and to determine the clinical characteristics and the prognosis of this rare entity.
  • The adjacent parenchyma contained fibrocystic dystrophy lesions associated in one case to intralobular neoplasia lesions.
  • CONCLUSION: Every benign mammary nodule must necessarily be verified surgically to avoid misdiagnosing any carcinomatous area because at this stage its prognosis is better.
  • [MeSH-major] Adenofibroma / pathology. Breast Neoplasms / pathology. Carcinoma / pathology. Cell Transformation, Neoplastic / pathology
  • [MeSH-minor] Adult. Breast Cyst / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy. Metaplasia. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236815.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


12. Liao MN, Chen MF, Chen SC, Chen PL: Uncertainty and anxiety during the diagnostic period for women with suspected breast cancer. Cancer Nurs; 2008 Jul-Aug;31(4):274-83
MedlinePlus Health Information. consumer health - Stress.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncertainty and anxiety during the diagnostic period for women with suspected breast cancer.
  • A possible diagnosis of breast cancer imposes a huge psychological impact on most women, but few studies have addressed uncertainty and anxiety changes at different diagnostic stages in women with suspected breast cancer.
  • Thus, this longitudinal study examined uncertainty and anxiety and predictive factors for uncertainty in women with suspected breast cancer.
  • Data were collected on uncertainty (Uncertainty in Illness Scale) and anxiety (State Anxiety Inventory) from 127 women at 3 times: upon notice of a breast biopsy, before biopsy, and after diagnosis.
  • The results showed that uncertainty and anxiety levels were significantly higher before than after diagnosis.
  • At the 3 data collection times, uncertainty and anxiety were significantly lower for participants diagnosed with benign tumors than for those with malignant diagnoses.
  • Uncertainty was predicted by age, marital status, education level, religious status, family history of benign breast tumor, regular breast self-examination, self-perceived probability of receiving a breast cancer diagnosis, and biopsy result.
  • Therefore, nursing professionals should be aware of the uncertainty and anxiety changes and impact of personal attributes on women with suspected breast cancer during the diagnostic period and provide care programs to alleviate their psychological distress.
  • [MeSH-major] Anxiety / etiology. Biopsy. Breast Neoplasms / diagnosis. Breast Neoplasms / psychology. Stress, Psychological / etiology


13. Eom M, Han A, Yi SY, Shin JJ, Cui Y, Park KH: RHEB expression in fibroadenomas of the breast. Pathol Int; 2008 Apr;58(4):226-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RHEB expression in fibroadenomas of the breast.
  • Although fibroadenoma is one of the most common types of benign breast tumor, genes specific to the tumor have not been identified.
  • RT-PCR for RHEB indicated increased expression of RHEB in fibroadenoma compared to breast cancer.
  • When studied with real-time PCR, the average RHEB/beta-actin ratio in fibroadenoma samples was 1.99, 2.46-fold greater than the average RHEB/beta-actin ratio in breast carcinoma of 0.81 (P < 0.01).
  • Therefore, RHEB could be used cytopathologically to distinguish fibroadenoma from malignant breast carcinomas as a secondary diagnostic tool.
  • [MeSH-major] Breast Neoplasms / genetics. Fibroadenoma / genetics. Gene Expression Regulation, Neoplastic. Monomeric GTP-Binding Proteins / genetics. Neuropeptides / genetics
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Mastectomy. Microdissection. Oligonucleotide Array Sequence Analysis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324915.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neuropeptides; 0 / RHEB protein, human; 0 / RNA, Messenger; EC 3.6.5.2 / Monomeric GTP-Binding Proteins
  •  go-up   go-down


14. Takehara K, Miyamoto K, Kawakami Y, Kumagai M, Samura O, Egawa M, Nakamura H, Mizunoe T, Taniyama K, Saji F: Epigenetic alteration of BRCA1 in human ovarian tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e16532

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic alteration of BRCA1 in human ovarian tumors.
  • : e16532 Background: The breast cancer susceptibility gene 1 (BRCA1) is mutated in half of hereditary breast cancers, and in about 80% of hereditary breast and ovarian cancers.
  • Also, BRCA1 expression is decreased in sporadic breast cancers by other mechanisms, such as epigenetic alteration, suggesting its important role in sporadic breast cancers.
  • The epigenetic alteration of BRCA1 and its contribution in sporadic ovarian tumors are not fully understood.
  • METHODS: We evaluated the DNA methylation status of the BRCA1 5' CpG island by methylation-specific PCR in 12 human ovarian cancer cell lines and 39 primary epithelial ovarian tumor specimens.
  • Cases included the following: malignant (n = 16), borderline (n = 8), and benign (n = 16) tumors.
  • RESULTS: BRCA1 was hypermethylated in one of 12 (8%) ovarian cancer cell lines and 15 of 39 (38%) primary ovarian tumors.
  • Relative to clinicopathological features, BRCA1 methylation was detected in 39% of malignant and borderline tumors and in 38% of benign tumors, suggesting the importance of BRCA1 pathway in both types of tumors.
  • CONCLUSIONS: BRCA1 was found to be frequently hypermethylated both in benign and malignant ovarian tumors.
  • Our results suggest that epigenetic alteration of BRCA1 might play a role in the development of benign and malignant sporadic ovarian tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960779.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Santana-Davila R, Visscher DW, Vachon CM, Frost M, Vierkant RA, Anderson SS, Degnim AC, Hartmann LC: Clinicopathological characteristics of subsequent breast cancers in patients with benign breast disease. J Clin Oncol; 2009 May 20;27(15_suppl):1061

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of subsequent breast cancers in patients with benign breast disease.
  • : 1061 Background: Benign breast disease (BBD) is a significant risk factor for breast cancer (BC); however little is known about the aggressiveness of the BCs these patients develop.
  • METHODS: The Mayo BBD cohort includes 9,376 women who had benign breast biopsies from 1967-1991.
  • Tissue from the BCs was reviewed by a single breast pathologist (DWV).
  • With a median of 18 years of follow-up, 799 patients with BBD have developed breast cancer, 416 initially had NP, 313 had PDWA, and 70 AH.
  • In 537 cases the malignant tissue had a concurrent benign component consisting of NP in 24% (n = 129), PDWA in 25.1% (n = 135), and AH in 50.8% (n = 273).
  • In regards to tumor size, 69.6% had T1 tumors, 24.9% T2 tumors, and 5.5% T3 disease.
  • Median time to BC was 12.3 years and did not differ across the different benign entities.
  • Breast cancer developed within 5 years from the initial BBD in 163 women (20%).
  • In this group, tumor size was greater (p = 0.02), and there were more poorly differentiated tumors (p = 0.006) than in those who later developed BC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961167.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Wang X, Li Y, Cao X: False-positive diagnosis of breast cancer by diffused optical tomography with ultrasound. J Clin Oncol; 2009 May 20;27(15_suppl):e22085

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False-positive diagnosis of breast cancer by diffused optical tomography with ultrasound.
  • : e22085 Background: Breast cancer is one of the most common cancer in women.
  • Early detection, early diagnosis and early treatment play key role in fighting against breast cancer.
  • It provides dual modality images for early diagnosis of breast cancer.
  • The aim of this study was to evaluate the OPTIMUS system on diagnosis of breast disease.
  • METHODS: OPTIMUS system was applied to 160 breast tumor patients.
  • All patients had received surgical treatment and had definite pathological diagnosis.
  • OPTIMUS system was evaluated as diagnostic tool of breast tumor in this study.
  • RESULTS: There were 42 cases diagnosed as benign breast disease and 118 cases diagnosed as breast cancer by OPTIMUS system.
  • Pathology confirmed 60 cases of benign disease and 100 cases of breast cancer.
  • False positive rate of breast cancer was 30% (18/60).
  • False negative rate of breast cancer was 0% (0/100).
  • Papillomatosis and non-typical hyperplasia are precancerous lesions and often difficult for clinical diagnosis.
  • CONCLUSIONS: OPTIMUS system is a non- invasive and highly effective diagnostic tool for breast disease.
  • Its sensitivity is reached to 100% and specificity is about 70% on the diagnosis of breast cancer.
  • OPTIMUS system could be used as assistant diagnostic tool for breast tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963263.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Buess M, Rajski M, Vogel B, Herrmann R, Rochlitz C: Tumor endothelial interaction, CD44+/CD24- stem cell signature, and prognosis in early-stage breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor endothelial interaction, CD44+/CD24- stem cell signature, and prognosis in early-stage breast cancer.
  • : 503 Background: The effects of tumor-endothelial interaction on global gene expression in breast cancer are not yet well characterized.
  • We hypothesized that gene expression signatures induced by tumor-endothelial interaction might be of clinical relevance.
  • METHODS: To this aim we set up an ex vivo co-culture model with human benign and a panel of 6 malignant breast epithelial cells in combination with human venous and microvascular endothelial cells and determined associated gene expression changes with cDNA microarrays.
  • Pretreatment gene expression profiles of 295 early stage breast cancers from the Netherlands Cancer Institute with a median follow up of 12.6 years allowed evaluating in vitro effects in vivo.
  • RESULTS: The most prominent response to co-culture was the induction of a set of "M-phase cell cycle" genes in a subset of breast cancer co-cultures, which were absent in co-cultures with normal breast epithelial cells.
  • While in monoculture tumor cells containing the stem cell like CD44+/CD24- signature showed a lower expression of the "M-phase cell cycle" genes than the CD44-/CD24+ cells, in the co-cultures with CD44+/CD24- cells these genes were induced.
  • Interestingly, these tumor cells co- expressed a set of angiogenic factors such as VEGF, PTN, and FGF12 mRNA at significantly higher levels.
  • In vivo, the expression of the gene set derived from the co-culture was remarkably coherent providing a basis for segregation of tumors into two groups.
  • In a univariate analysis, early stage tumors with high expression levels (n= 137) of "M-phase cell cycle" genes had a significantly lower distant metastasis-free survival (p=1.8e-5) (50 % at 10 years) and overall survival rate (p= 5e-9) (52 % at 10 years) than tumors with low expression levels (n= 158) (metastasis-free survival: 73 %; overall survival: 84 % at 10 years).
  • CONCLUSIONS: Our results suggest that the interaction of tumor cells expressing the CD44+/CD24- stem cell like signature, implicating a low proliferative potential, with endothelial cells might explain the unexpected and paradoxical association of the CD44+/CD24- signature with highly proliferative tumors with an unfavorable prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960783.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Desiris K, Voyatzi S, Stravoravdi P, Boukovinas I, Kiziridou A, Paikos D, Stergiou E, Sibilidis G: Detection of methylation in the CpG islands of the RASSF1A and RAR2b gene promoters in breast cancer (BC). J Clin Oncol; 2009 May 20;27(15_suppl):e14632

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of methylation in the CpG islands of the RASSF1A and RAR2b gene promoters in breast cancer (BC).
  • METHODS: Promoter methylation was measured in 37 pts, 26 with BC and 11 with benign lesions.
  • The specimens were obtained from archive formalin-fixed paraffin-embedded tumors.
  • Correlation between methylation and clinicopathological features revealed an association of the RASSF1A gene with T2 tumors (12/15 pts, p<0.05) and ER (+) status (12/15 pts, p<0.05).
  • T2 tumors and ER (+) status presented together in 9/15 pts.
  • In benign lesions methylation of at least one of the genes was observed in 8/11 pts (p<0.05).
  • CONCLUSIONS: Both genes are frequently methylated in both benign and malignant breast lesions.
  • The association of methylation of RASSF1A gene with tumor size and ER status is noteworthy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964178.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Aharinejad S, Thomas A, Singer C, Kubista E, Paulus P, Miksovsky A, Abraham D: Significance of serum colony-stimulating factor-1 as a breast cancer marker. J Clin Oncol; 2009 May 20;27(15_suppl):11071

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of serum colony-stimulating factor-1 as a breast cancer marker.
  • : 11071 Background: A specific and sensitive biomarker that indicates the presence of breast cancer is highly desirable, yet available markers are of limited value.
  • Colony-stimulating factor-1 (CSF-1) is involved in mammary gland development and mediates breast cancer progression.
  • Earlier work indicated correlation of serum CSF-1 with breast cancer staging, and a recent report suggests that CSF-1 is a potential breast cancer marker, however the data reported so far await validation.
  • In this cohort, 312 patients had breast cancer and 487 age-matched women had benign tumors.
  • The tumor size, nodal and metastasis status, histological tumor type, hormone and human epidermal growth factor receptor 2 (HER2) and menopausal status were evaluated.
  • RESULTS: Mean serum CSF-1 concentrations were significantly higher in all patients with malignant tumors (502±429 pg/mL) as compared to those with benign tumors (382±344 pg/mL) (p<0.0001, Wilcoxon).
  • Increased CSF-1 levels in patients with malignant tumors were associated with postmenopausal (p=0.0038) but not premenopausal (p=0.94) status (Wilcoxon).
  • Serum CSF-1 concentrations did not correlate significantly with tumor size, nodal and metastasis status, hormone receptor and HER2 status of patients (Kruskal-Wallis).
  • CONCLUSIONS: Our data suggest that serum CSF-1 could serve as a breast cancer marker in postmenopausal women.
  • While its serum levels are not related to breast cancer stage at diagnosis, they might be useful for breast cancer screening in postmenopausal women.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963190.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Liu JT, Yue J, Ren XB, Li H: [Measurement of CD4+CD25+ T cells in breast cancer patients and its significance]. Zhonghua Zhong Liu Za Zhi; 2005 Jul;27(7):423-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Measurement of CD4+CD25+ T cells in breast cancer patients and its significance].
  • OBJECTIVE: To evaluate the changes of CD(4)(+)CD(25)(+) T cells in peripheral blood from patients with breast cancer.
  • METHODS: Sixty four patients with breast cancer, 15 patients with benign breast tumors and 9 healthy volunteers were included in this study.
  • RESULTS: The population of CD(4)(+)CD(25)(+) T cells in peripheral blood from patients with breast cancer accounted for (5.1 +/- 2.9)% of the total amount of T lymphocytes, and was significantly higher in comparison with that in patients with benign tumors and in healthy volunteers (P < 0.05).
  • The CD(4)(+)CD(25)(+) T cells population in breast cancer patients was positively correlated with the cancer size and with TGF-beta1 level (r = 0.511 and r = 0.253, respectively), and negatively correlated with CD(8)(+)CD(28)(+) T cells and NK cells (r = -0.243 and r = -0.301, respectively).
  • CONCLUSION: The CD(4)(+)CD(25)(+) regulatory T cells in peripheral blood of patients with breast cancer is significantly increased in comparison with that in patients with benign breast tumor and in healthy subjects.
  • It may be responsible for immune suppression in breast cancer patients.
  • [MeSH-major] Breast Neoplasms / immunology. CD4-Positive T-Lymphocytes / immunology. Interleukin-2 Receptor alpha Subunit / immunology. T-Lymphocyte Subsets / immunology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16188129.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-2 Receptor alpha Subunit; 0 / Transforming Growth Factor beta
  •  go-up   go-down


21. Streckfus CF, Mayorga-Wark O, Arreola D, Edwards C, Bigler L, Dubinsky WP: Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast. Cancer Invest; 2008 Mar;26(2):159-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast.
  • OBJECTIVE: The objective of this study was to determine if protein-by-products secondary to cancer related oncogenes appear in the saliva of breast cancer patients.
  • One pooled specimen was from healthy women, another pooled specimen from women diagnosed with a benign breast tumor and the other one pooled specimen was from women diagnosed with ductal carcinoma in situ (DCIS).
  • Differential expression of proteins was measured by isotopically tagging proteins in the tumor groups and comparing them to the healthy control group.
  • Forty-nine proteins were differentially expressed between the healthy control pool and the benign and cancer patient groups.
  • Additionally, there may be salivary protein profiles that are unique to both DCIS and fibroadenoma tumors.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Fibroadenoma / metabolism. Neoplasm Proteins / metabolism. Saliva / metabolism. Salivary Proteins and Peptides / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259946.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Salivary Proteins and Peptides
  •  go-up   go-down


22. Chen YW, Chuang YW, Lai YC, Hsieh JS, Liu GC, Hou MF: Is early dynamic lymphoscintigraphy for detection of sentinel lymph nodes always achievable in breast tumor? Ann Nucl Med; 2006 Jan;20(1):45-50
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is early dynamic lymphoscintigraphy for detection of sentinel lymph nodes always achievable in breast tumor?
  • OBJECTIVE: In this article, we will discuss the achievement of early dynamic lymphoscintigraphic protocol and compare detection of sentinel node between benign and malignant breast tumors, and whether pathologic factor is related or not.
  • The average age of patients was 47.6 +/- 9.8 years and all of them were clinically suspected of having breast cancer.
  • The average tumor was 2.1 +/- 1.1 cm in size.
  • All patients underwent surgery sixteen to twenty hours later and had a final pathological diagnosis.
  • From the summation image of dynamic study, identified axillary sentinel nodal activity was found as 80% in the group of benign breast tumor, but only 48% in the group of malignant breast tumor.
  • However, this short period of protocol is not always achievable to detect sentinel node, especially in the group with breast malignant lesions.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Breast Neoplasms / secondary. Lymph Nodes / pathology. Lymph Nodes / radionuclide imaging. Sentinel Lymph Node Biopsy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485574.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


23. Eroğlu A, Sari A: Expression of c-kit proto-oncogene product in breast cancer tissues. Med Oncol; 2007;24(2):169-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-kit proto-oncogene product in breast cancer tissues.
  • BACKGROUND: The published results on expression of c-kit in benign and malignant breast tissues vary.
  • MATERIALS AND METHODS: The immunohistochemical expression of c-kit proto-oncogene product in 52 invasive breast cancer tissues and 16 benign breast tumor (fibroadenoma) tissues was studied using anti-c-kit proto-oncogene product antibody.
  • RESULTS: In breast cancer tissues, the mean IRS of c-kit proto-oncogene product expression was significantly increased compared to those of fibroadenoma (3.4 +/- 2 and 2.19 +/- 1.8, respectively,p = 0.035).
  • The mean IRS of c-kit expression was higher in the group comprising estrogen (ER) positive tumor than in the group of ER negative (4.1 +/- 2.1 and 2.7 +/- 1.8, respectively,p = 0.012) but no statistically significant relationship was seen between the expression of c-kit proto-oncogene product and other clinicopathological parameters of breast cancer, including histologic type, tumor size, lymph node metastasis, distant metastasis, stage, progesterone receptor, c-erbB-2 expression, menopausal status and age of the patient (p > 0.05).
  • CONCLUSIONS: Our results show that a high level of c-kit expression occurs frequently in invasive breast cancer, and its expression is associated with ER but unrelated to other clinico-pathological variables.
  • [MeSH-major] Breast Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848740.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


24. Shen C, Hu L, Xia L, Li Y: The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR. Clin Biochem; 2009 Feb;42(3):194-200
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR.
  • OBJECTIVES: To develop a specific, reliable assay for detecting circulating tumor cells (CTC) in peripheral blood of breast cancer patients.
  • DESIGN AND METHODS: 94 breast cancer patients, 35 patients with benign breast tumor, 40 healthy individuals, and 25 patients with other solid tumors were evaluated by quantitative real-time reverse transcription-PCR (qRT-PCR) for detecting Survivin, hTERT, and hMAM mRNA in peripheral blood (PB) of breast cancer patients.
  • RESULTS: The sensitivity of Survivin, hTERT, and hMAM mRNA in the PB of breast cancer patients was 36.2%, 59.6% and 33.0%, respectively.
  • Survivin and hTERT were detected in the PB patients with solid tumors other than breast cancer, but hMAM mRNA was only detected in breast cancer patients.
  • CONCLUSIONS: Survivin, hTERT and hMAM mRNA assays are powerful methods for detection of CTC of breast cancer patients.
  • With combination of the three markers for detection of CTC of breast cancer, the parallel test increases the sensitivity.
  • This analysis can offer a simple, noninvasive, and promising adjuvant tool for the early detection of micrometastatic tumor cells in breast cancer patients.
  • [MeSH-major] Breast Neoplasms / diagnosis. Neoplasm Metastasis / diagnosis. Neoplastic Cells, Circulating. RNA, Neoplasm / blood. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19022237.001).
  • [ISSN] 1873-2933
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / DNA-Binding Proteins; 0 / Inhibitor of Apoptosis Proteins; 0 / MAML1 protein, human; 0 / Microtubule-Associated Proteins; 0 / RNA, Neoplasm; 0 / Trans-Activators; 0 / Transcription Factors; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


25. Sheen-Chen SM, Liu YW, Eng HL, Chou FF: Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev; 2005 Mar;14(3):715-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of hepatocyte growth factor in patients with breast cancer.
  • Elevated hepatocyte growth factor content in tumor tissue was reported to predict a more aggressive biology in non-small cell lung cancer patients.
  • However, there is still limited knowledge about the role of HGF in breast cancer.
  • This study was designed with the aim to elucidate the possible relationship between the preoperative circulating soluble HGF and breast cancer.
  • MATERIALS AND METHODS: One hundred twenty-four consecutive patients with invasive breast cancer undergoing surgery were prospectively included and evaluated.
  • The control group consisted of 35 patients with benign breast tumor (20 with fibrocystic disease and 15 with fibroadenoma).
  • The data on primary tumor staging, age, estrogen receptor status, lymph node status, distant metastases status, histologic grading, and tumor-node-metastasis (TNM) staging were reviewed and recorded.
  • RESULTS: The mean value of serum soluble HGF in patients with invasive breast cancer was 529.05 +/- 123.33 pg/mL and that of control group was 343.00+/- 31.03 pg/mL and the difference was significant (P < 0.001).
  • Furthermore, there were significantly higher serum levels of soluble HGF in patients with negative estrogen receptor (P = 0.035), in patients with poorer differentiated tumor (P < 0.001), in patients with more advanced primary tumor staging (P < 0.001), in patients with more advanced lymph node status (P < 0.001), in patients with distant metastases (P < 0.001), and in patients with more advanced TNM staging (P < 0.001).
  • Thus, preoperative serum soluble HGF levels might reflect the severity of invasive breast cancer and deserve further evaluation.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / pathology. Hepatocyte Growth Factor / blood. Neoplasm Invasiveness
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Staging. Prospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767355.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


26. Ławicki S, Czygier M, Bedkowska E, Wojtukiewicz M, Szmitkowski M: Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors. Pol Arch Med Wewn; 2008 Sep;118(9):464-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors.
  • The direct production of this cytokine has been reported in tumor cell lines in vitro and in solid tumors in vivo.
  • OBJECTIVES: In the present study, the levels of M-CSF in patients with breast cancer and in those with a benign breast tumor were evaluated.
  • PATIENTS AND METHODS: The study group was made up of 70 patients with breast cancer and 20 patients with benign tumors and the control group of 30 healthy women.
  • RESULTS: Statistically higher levels of M-CSF and CA 15-3 were found in breast cancer patients as compared to the benign tumor and control groups.
  • The diagnostic sensitivity of M-CSF (58%), a specificity (93%), PV(+ve) (94%) and PV(-ve) (43%) were higher or equal to the values obtained for CA 15-3 (49%, 93%, 93% and 40%, respectively).
  • CONCLUSIONS: The above data suggests that M-CSF might be useful in both diagnostics and differential diagnosis of benign tumors and breast cancer (except for the lowest degree of the clinical progression).
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Macrophage Colony-Stimulating Factor / blood
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Poland. Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846980.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


27. Toth B, Liebhardt S, Steinig K, Ditsch N, Rank A, Bauerfeind I, Spannagl M, Friese K, Reininger AJ: Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost; 2008 Oct;100(4):663-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet-derived microparticles and coagulation activation in breast cancer patients.
  • We performed a prospective study on platelet-derived microparticles (PMP) and their procoagulant potential in breast cancer patients.
  • Fifty-eight breast cancer patients and 13 women with benign breast tumors were included in the study.
  • Numbers of annexin V+-MP were highest in breast cancer patients with larger tumor size (T2; median = 5,637 x 10(6)/l; range = 2,852-8,613) and patients with distant metastases (M1; median = 6,102 x 10(6)/l; range = 3,350-7,445), and differed significantly from patients with in-situ tumor (Tis; median = 3,220 x 10(6)/l; range = 2,277-4,124; p = 0.019), small tumor size (T1; median = 3,281 x 10(6)/l; range = 2,356-4,861; p = 0.043) and women with benign breast tumor (median = 4,108 x 10(6)/l; range = 2,530-4,874; p = 0.040).
  • Larger tumor size (T2) and metastases correlated with high counts of PMP and with highest F1+2 levels.
  • Since prothrombin levels and thrombin generation did not parallel MP levels, we speculate that MP act in the microenvironment of tumor tissue and may thus not be an exclusive parameter reflecting in-vivo procoagulant activity.
  • [MeSH-major] Blood Coagulation / physiology. Blood Platelets / pathology. Breast Neoplasms / complications. Thrombosis / complications. Thrombosis / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Endothelial Cells / pathology. Endothelial Cells / ultrastructure. Female. Flow Cytometry. Humans. Leukocytes / pathology. Leukocytes / ultrastructure. Microscopy, Electron. Middle Aged. Neoplasms / complications. Particle Size. Peptide Fragments / metabolism. Prospective Studies. Prothrombin / metabolism. Thrombin / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841290.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / prothrombin fragment 1.2; 9001-26-7 / Prothrombin; EC 3.4.21.5 / Thrombin
  •  go-up   go-down


28. Strumylaite L, Bogusevicius A, Ryselis S, Pranys D, Poskiene L, Kregzdyte R, Abdrachmanovas O, Asadauskaite R: [Association between cadmium and breast cancer]. Medicina (Kaunas); 2008;44(6):415-20
Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association between cadmium and breast cancer].
  • Cadmium is a known human lung carcinogen, although some studies indicate a link between cadmium exposure and human breast cancer.
  • The objective of this study was to assess cadmium concentration in breast tissue samples of patients with breast cancer and benign breast tumor.
  • The concentration of cadmium was determined in breast tissue samples of 21 breast cancer and 19 benign tumor patients.
  • Two samples of breast tissue from each patient, i.e. tumor and normal tissue close to tumor, were taken for the analysis.
  • RESULTS. In patients with breast cancer, the mean cadmium concentration was 33.1 ng/g (95% CI, 21.9-44.4) in malignant breast tissue and 10.4 ng/g (95% CI, 5.6-15.2) in normal breast tissue (P=0.002).
  • In patients with benign tumor, the corresponding values were 17.5 ng/g (95% CI, 8.4-26.5) and 11.8 ng/g (95% CI, 5.1-18.5) (P=0.3144).
  • There was a statistically significant difference in cadmium concentration between malignant and benign breast tissues (P=0.009).
  • CONCLUSION. The data obtained show that cadmium concentration is significantly higher in malignant breast tissue as compared with normal breast tissue of the same women or benign breast tissue.
  • Further studies are necessary to determine the association between cadmium concentration in malignant breast tissue and estrogen receptor level, and smoking.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Breast / chemistry. Breast Neoplasms / chemistry. Cadmium / analysis. Carcinoma in Situ / chemistry. Carcinoma, Ductal, Breast / chemistry

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18660635.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 00BH33GNGH / Cadmium
  •  go-up   go-down


29. Zanetti-Dallenbach RA, Schmid S, Wight E, Holzgreve W, Ladewing A, Hahn S, Zhong XY: Levels of circulating cell-free serum DNA in benign and malignant breast lesions. Int J Biol Markers; 2007 Apr - Jun;22(2):95-99

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of circulating cell-free serum DNA in benign and malignant breast lesions.
  • : Purposes of the study: We analyzed circulating cell-free DNA in the serum of patients with benign and malignant breast disease and in healthy individuals to determine its diagnostic value.
  • BASIC PROCEDURES: Serum samples were obtained from 50 healthy individuals, 33 patients with malignant breast disease and 32 patients with benign breast disease.
  • Tissue samples from patients with malignant and benign breast lesions were histopathologically examined.
  • MAIN FINDINGS: The mean levels of circulating cell-free DNA in serum samples were 41,149 genome equivalents (GE)/mL in patients with malignant disease, 30,826 GE/mL in patients with benign disease, and 13,267 GE/mL in healthy individuals.
  • Healthy individuals had significantly lower levels of cell-free DNA than patients with malignant or benign breast disease (p=0.001, p=0.031).
  • No significant difference was observed between malignant and benign disease.
  • There was a correlation between cell-free DNA levels and tumor size but not with other tumor characteristics.
  • PRINCIPAL CONCLUSION: Our results suggest that levels of circulating cell-free DNA in serum could have diagnostic value to discriminate between healthy individuals and patients with breast lesions but not between patients with malignant and benign breast lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207146.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


30. Yang GZ, Li J, Ding HY: [Nipple adenoma: report of 18 cases with review of literatures]. Zhonghua Bing Li Xue Za Zhi; 2009 Sep;38(9):614-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinicopathological and immunohistochemical features, diagnosis and differential diagnosis of nipple adenoma of the breast.
  • RESULTS: The neoplasms were localized at nipples or under the areola of breast, adherent to the epidermis, mainly composed of dilated ducts in a tubular appearance associated with fibrotic matrix.
  • The tumor cells were crowding, lack of an uniform morphology and polarity with intact myoepithelial cells around the ducts.
  • CONCLUSIONS: Nipple adenoma is an infrequent type of benign breast neoplasm, presenting as sclerosing papilloma, papillomatosis or florid sclerosing adenosis.
  • A correct diagnosis is based on the peculiar location and morphology of the tumor, and immunohistochemistry is helpful in some cases.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology. Nipples / pathology
  • [MeSH-minor] Adult. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Keratin-5 / metabolism. Keratins / metabolism. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079190.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CK-34 beta E12; 0 / Keratin-5; 68238-35-7 / Keratins
  •  go-up   go-down


31. Khoo JJ, Alwi RI, Abd-Rahman I: Myoid hamartoma of breast with chondroid metaplasia: a case report. Malays J Pathol; 2009 Jun;31(1):77-80
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myoid hamartoma of breast with chondroid metaplasia: a case report.
  • Breast hamartoma is an uncommon poorly recognised benign breast neoplasm.
  • Hamartoma displaying marked smooth muscle components known as myoid hamartoma of the breast is a much rarer entity.
  • We present a case of myoid hamartoma of breast with chondroid differentiation in a 46-year-old woman.
  • The painless breast lump was circumscribed and mammography showed a well-encapsulated large, dense mass with no calcification.
  • The various immuno-histochemical staining as well as the cyto-histological changes encountered in myoid hamartomas are discussed with clinical, radiological and pathological correlation to differentiate it from other benign and malignant breast lesions.
  • [MeSH-major] Breast Diseases / pathology. Hamartoma / pathology. Muscle, Smooth / pathology
  • [MeSH-minor] Biomarkers / metabolism. Breast Neoplasms / diagnosis. Cartilage / pathology. Cell Differentiation. Diagnosis, Differential. Female. Fibroadenoma / diagnosis. Humans. Immunohistochemistry. Metaplasia / pathology. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694319.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


32. Huang YL, Chen DR, Jiang YR, Kuo SJ, Wu HK, Moon WK: Computer-aided diagnosis using morphological features for classifying breast lesions on ultrasound. Ultrasound Obstet Gynecol; 2008 Sep;32(4):565-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-aided diagnosis using morphological features for classifying breast lesions on ultrasound.
  • OBJECTIVES: To develop and evaluate a computer-aided diagnosis (CAD) system with automatic contouring and morphological analysis to aid in the classification of breast tumors using ultrasound.
  • METHODS: We evaluated 118 breast lesions (34 malignant and 84 benign tumors).
  • Each tumor contour was automatically extracted from the digitized ultrasound image.
  • A support vector machine (SVM) classifier utilized the selected principal vectors to identify the breast tumor as benign or malignant.
  • The classification ability for breast tumors using morphological information was good.
  • CONCLUSIONS: This system differentiates benign from malignant breast tumors well and therefore provides a clinically useful second opinion.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Diagnosis, Computer-Assisted / methods. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Aged. Algorithms. Diagnosis, Differential. Female. Humans. Image Interpretation, Computer-Assisted / methods. Middle Aged. Principal Component Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383556.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


33. Huang YL, Kuo SJ, Chang CS, Liu YK, Moon WK, Chen DR: Image retrieval with principal component analysis for breast cancer diagnosis on various ultrasonic systems. Ultrasound Obstet Gynecol; 2005 Oct;26(5):558-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image retrieval with principal component analysis for breast cancer diagnosis on various ultrasonic systems.
  • OBJECTIVES: We present a computer-aided diagnostic (CAD) system with textural features and image retrieval strategies for classifying benign and malignant breast tumors on various ultrasonic systems.
  • This study evaluated a series of pathologically proven breast tumors using various ultrasonic systems.
  • METHODS: Altogether, 600 ultrasound images of solid breast nodules comprising 230 malignant and 370 benign tumors were investigated.
  • The suspicious tumor area in the ultrasound image was manually chosen as the region-of-interest (ROI) subimage.
  • Textural features extracted from the ROI subimage are supported in classifying the breast tumor as benign or malignant.
  • In practice, high-dimensional vectors are unsatisfactory at differentiating breast tumors.
  • The image retrieval techniques were employed to differentiate breast tumors, according to the similarities of the principal vectors.
  • The query ROI subimages were identified as malignant or benign tumors according to characteristics of retrieved images from the ultrasound image database.
  • CONCLUSION: The CAD system identified solid breast nodules with comparatively high accuracy in the different ultrasound systems investigated.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Image Interpretation, Computer-Assisted / methods
  • [MeSH-minor] Area Under Curve. Breast Diseases / classification. Breast Diseases / ultrasonography. Databases, Factual. Female. Humans. Principal Component Analysis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 ISUOG.
  • (PMID = 16086435.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


34. Ditsch N, Liebhardt S, Von Koch F, Lenhard M, Vogeser M, Spitzweg C, Gallwas J, Toth B: Thyroid function in breast cancer patients. Anticancer Res; 2010 May;30(5):1713-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid function in breast cancer patients.
  • BACKGROUND: Recent studies indicate a possible relationship between hypothyroidism and breast cancer in vivo.
  • In addition, oestrogen-like effects of thyroid hormones on breast cancer cell growth are seen in vitro.
  • Therefore, this study evaluated thyroid function in breast cancer patients, women with benign breast tumour and healthy controls.
  • PATIENTS AND METHODS: Breast cancer patients (n=65), women with carcinoma in situ (n=13) or benign breast tumour (n=27), and healthy controls (n=38) were included in the study.
  • RESULTS: fT3 and fT4 levels were highest in breast cancer patients, and differed significantly from controls (fT3 and fT4: p<0.001) as well as from patients with benign breast tumour (fT3: p=0.021; fT4: p=0.017).
  • With regard to TRAK antibodies, breast cancer patients showed the highest levels differing significantly from women with benign breast tumours (p=0.048).
  • CONCLUSION: Significant differences in fT3/fT4 as well as TRAK levels were observed among breast cancer patients, women with benign breast tumours and healthy controls.
  • [MeSH-major] Breast Neoplasms / physiopathology. Thyroid Gland / physiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592366.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Estrogens; 0 / Thyroid Hormones
  •  go-up   go-down


35. Kamate B, Traore CB, Diallo D, Foko I, Sangare F, Malle B, Coulibaly B, Mounkoro N, Bayo S: [Epidemiology and morphology of breast benign tumors in Mali: about 186 cases]. Mali Med; 2008;23(3):36-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiology and morphology of breast benign tumors in Mali: about 186 cases].
  • [Transliterated title] Epidemiologie et morphologie des tumeurs benignes du sein au Mali: a propos de 186 cas.
  • BACKGROUND: Mammary tumors are frequent.
  • Benign tumors are more frequent, and are characterized by a possibility of recurrence or malignant transformation.
  • The aim of this study was to describe the epidemiological and morphological characteristics of breast benign tumors.
  • The study had concerned all benign tumors confirmed by histology.
  • FINDINGS: In total, 186 benign tumors were diagnosed over 611 mammary pathologies (30.44%).
  • The main complaint was feeling a nodule in the breast (91.9%).
  • The most affected breast was the right side (50.8%).
  • Tumor sizes were variable, and the color changed through white to yellow.
  • Histological aspects were: fibroadenoma (72%), lipoma (8.6%), tubular adenoma (5.9%), papilloma (5.4%), lactating adenoma (3.8%), phyllodes tumor (3.8%), and syringomatous tumor (0.5%).
  • CONCLUSION: Benign tumors are frequent in mammary pathology.
  • The patients need a follow-up because of the recurrence or the malignant transformation of these tumors.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617151.001).
  • [ISSN] 1993-0836
  • [Journal-full-title] Le Mali médical
  • [ISO-abbreviation] Mali Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mali
  •  go-up   go-down


36. Cashell AW: Apocrine adenoma of the breast. W V Med J; 2008 Mar-Apr;104(2):16-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine adenoma of the breast.
  • A case of apocrine adenoma, a rare benign tumor of the breast is reported.
  • A left breast nodule from a 47-year-old female was found by mammography and excised.
  • The tumor was well circumscribed and composed of tightly packed tubules lined by cells with apocrine features.
  • Apocrine adenomas have been reported arising in a variety of sites including the breast, (1-5) perianal region, (6,7) eyelid, (8) and axilla. (9) Their appearance has similarities to the apocrine metaplasia commonly seen in fibrocystic change of the breast but they are well-circumscribed tumors with closely packed tubular and papillary structures.
  • They are not distinctive by mammography or physical examination and should be managed as any other breast mass.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Apocrine Glands / pathology. Breast Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Female. Humans. Mammography. Middle Aged. Ultrasonography, Mammary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18491794.001).
  • [ISSN] 0043-3284
  • [Journal-full-title] The West Virginia medical journal
  • [ISO-abbreviation] W V Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Kinkor Z, Havlícek F, Michal M: [Benign mesenchymal stromal tumor of the breast simulating benign schwannoma in an 81-year-old male--a case report]. Cesk Patol; 2006 Oct;42(4):186-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign mesenchymal stromal tumor of the breast simulating benign schwannoma in an 81-year-old male--a case report].
  • [Transliterated title] Benigní vretenobunecný stromální tumor prsu podobný schwannomu u 81letého muze-- kazuistika.
  • Presented is an unusual case of a benign mesenchymal stromal tumor of the breast in an 81-year-old male.
  • The basic appearance of the lesion simulated benign schwannoma and was misinterpreted as a low-grade myxoid liposarcoma initially.
  • Well-circumscribed, gray-white mass measuring 35 mm in maximum diameter was discovered deep in the parenchyma of the completely removed breast.
  • Microscopically, the lesion consisted of myxoid, richly vascular background where dominated oval or spindle cells with impressive palisading replicating that of benign schwannoma.
  • On the background of both detailed review and differential diagnosis of benign, so-called stromal tumor of the female breast, the rarity of this microscopic finding in male is documented.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Liposarcoma, Myxoid / pathology. Neurilemmoma / pathology. Stromal Cells / pathology
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17171974.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


38. Devi PM, Singh LR, Gatphoh ED: Fibroadenoma with squamous metaplasia. Singapore Med J; 2007 Jul;48(7):682-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibroadenoma is the most common benign breast tumour in adolescent and young women.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Fibroadenoma / pathology
  • [MeSH-minor] Adult. Female. Fibrocystic Breast Disease / complications. Fibrocystic Breast Disease / pathology. Humans. Metaplasia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609833.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


39. Buch A, Rout P, Makhija P: Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump. Indian J Pathol Microbiol; 2006 Apr;49(2):259-61
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump.
  • An unusual combination of two benign breast neoplasms adenomyoepithelioma and phyllodes tumor presenting as a solitary breast lump have been described.
  • Both these tumors have tendencies to recur and have malignant potential.
  • This patient also presented with a recurrent breast neoplasm.
  • [MeSH-major] Adenomyoma / pathology. Breast Neoplasms / pathology. Myoepithelioma / pathology. Neoplasms, Multiple Primary / pathology. Phyllodes Tumor / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Indian J Pathol Microbiol. 2006 Jul;49(3):476
  • (PMID = 16933731.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


40. Ikeda S, Shibata T, Funakoshi N: Immunohistochemical detection of telomerase reverse transcriptase (TERT) protein in benign and malignant tumor cells of the breast. Rinsho Byori; 2005 Jun;53(6):487-93
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of telomerase reverse transcriptase (TERT) protein in benign and malignant tumor cells of the breast.
  • Telomerase activity is associated with immortality and is expressed in various malignant tumors.
  • In this study, the expression of TERT was investigated by immunocytochemistry to determine whether it is a useful marker for differential diagnosis in benign or malignant breast tumors.
  • We examined imprint smears prepared from 63 surgically resected breast lesions, and 27 cases of secretion or aspiration cytology smears had been routinely diagnosed.
  • In conclusion, the expression of TERT protein might be a useful marker for differential diagnosis in malignant and benign breast tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. DNA-Binding Proteins / analysis. Telomerase / analysis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. In Situ Hybridization. RNA, Messenger / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rinsho Byori.2005 Aug;53(8):748
  • (PMID = 16026073.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


41. Anyikam A, Nzegwu MA, Ozumba BC, Okoye I, Olusina DB: Benign breast lesions in Eastern Nigeria. Saudi Med J; 2008 Feb;29(2):241-4
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign breast lesions in Eastern Nigeria.
  • OBJECTIVE: To characterize benign breast diseases in Eastern Nigeria and to highlight the age variations of these lesions as base line data.
  • Seven hundred and twenty-two benign breast specimens were analyzed over 5 years from 1st January 2000 to 31st December 2004, out of 1050 breast samples received.
  • RESULTS: Of 1050 breast specimens received, 722 (68.8%) were benign.
  • Normal breast in the axillary tail region was seen in 32 cases (4.4%), represented as no pathology, with a mean presentation age of 20-46 years.
  • Low grade Phyllodes tumor had 28 cases (3.9%), presenting at an average mean age of 17-32 years.
  • Benign breast lesions peaked at the 20-24 age range and then declined.
  • CONCLUSION: Benign breast lesions occur more frequently than malignant breast lesions with a ratio of 2.3:1 and were presented 20 years earlier than their malignant counterparts.
  • Fibroadenoma was the most common benign lesion followed by fibrocystic disease, similar to the findings in Western Nigeria.
  • In Northern Nigeria, fibrocystic breast disease was more common.
  • [MeSH-major] Breast Diseases / epidemiology. Breast Neoplasms / epidemiology. Fibroadenoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Female. Fibrocystic Breast Disease / epidemiology. Gynecomastia / epidemiology. Humans. Male. Middle Aged. Nigeria / epidemiology. Phyllodes Tumor / epidemiology. Sex Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246234.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


42. Hikino H, Nagaoka S, Miura H, Kurosumi M: Benign myoepithelioma of the breast: origin and development. Pathol Int; 2009 Jun;59(6):422-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign myoepithelioma of the breast: origin and development.
  • A case of benign myoepithelioma of the breast in a 55-year-old woman is described.
  • The tumor was a well-circumscribed solid mass, measuring 13 x 12 mm.
  • Histopathology indicated that the tumor was composed of entirely myoepithelial cells, which was confirmed by immunoreactivity to calponin and S-100.
  • There was no ductal differentiation in the tumor, and staining for pan-cytokeratin and epithelial membrane antigen was weak and negative, respectively.
  • Although the biological behavior of the tumor remains to be ascertained, the tumor was considered to be myoepithelioma with benign features due to mild nuclear pleomorphism, sparse mitotic figures, low Ki-67 labeling index and low S-phase fraction.
  • Diagnostic confusion between benign myoepithelioma and other myoepithelial-rich cell tumors is possible.
  • Considering the classification of myoepithelial tumor in the salivary glands, benign myoepithelioma of the breast may possess a different development process from adenomyoepithelioma.
  • [MeSH-major] Breast Neoplasms / pathology. Myoepithelioma / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Mastectomy. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19490475.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


43. Thitaikumar A, Mobbs LM, Kraemer-Chant CM, Garra BS, Ophir J: Breast tumor classification using axial shear strain elastography: a feasibility study. Phys Med Biol; 2008 Sep 7;53(17):4809-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast tumor classification using axial shear strain elastography: a feasibility study.
  • In this paper, we report a feasibility study on the utility of the axial-shear strain elastograms in the classification of in vivo breast tumor as being benign or malignant.
  • The study was performed using data sets obtained from 15 benign and 15 malignant cases that were biopsy proven.
  • The observers also outlined the tumor area on the corresponding sonogram, which was used to normalize the area of the axial-shear strain region.
  • First, the result indicates that the observers consistently ( approximately 82% of the cases) noticed the characteristic pattern of the axial-shear strain distribution data as predicted in the previous simulation studies, i.e. alternating regions of positive and negative axial-shear strain values around the tumor-background interface.
  • Second, the analysis of the result suggests that in approximately 57% of the cases in which the observers did not visualize tumor in the sonogram, the elastograms helped them to locate the tumor.
  • Feature values between 0.46 and 0.75 may result in an overlap between benign and malignant cases.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Elasticity Imaging Techniques / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701768.001).
  • [ISSN] 0031-9155
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Kim SH, Miller FR, Tait L, Zheng J, Novak RF: Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions: biomarkers of progression. Int J Cancer; 2009 Jun 15;124(12):2813-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions: biomarkers of progression.
  • The MCF10A human breast epithelial cell lineage includes the benign MCF10A cells, premalignant cells (MCF10AT, MCF10ATG3B) and malignant MCF10CA1a tumor cells.
  • The premalignant and tumor cells recapitulate the progressive alterations associated with the temporal development of PBD and carcinoma.
  • K-Ras was not detected, N-Ras levels were unchanged; Rac and Rho levels increased in 10CA1a tumor cells.
  • Phospho-phosphatidylinositol 3-kinase, phosphoinositide-dependent protein kinase 1 (PDK1), phospho-PDK1, phospho-eukaryotic translation initiation factor 4E (eIF4E) and phospho-eukaryotic initiation factor 4E binding protein 1 (4E-BP1) levels progressively increased in the cell lineage, with the greatest increase monitored in 10CA1a tumor cells.
  • Immunohistochemistry confirmed Ras, phospho-Akt and phospho-p70S6K (Thr 421/ Ser 424) expression in lesions arising from premalignant and tumor cells.
  • FOXO 1, phospho-FOXO 1 and phospho-FOXO 4 were significantly elevated in 10ATG3B premalignant and 10CA1a tumor cells.
  • Phospho-FOXO 3a was progressively elevated, with the greatest levels detected in 10CA1a tumor cells.
  • Immunohistochemistry revealed that phospho-FOXO 1, 3a and 4 staining was less in benign lesions, but elevated in advanced 10ATG3B and malignant 10CA1a lesions, showing a correspondence between the cells and lesions.
  • Hence, phospho-Akt and phospho-FOXO 1, 3a and 4 merit consideration as biomarkers of tumorigenic risk from hyperplastic breast tissue.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 UICC.
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] EMBO J. 1996 Dec 2;15(23):6541-51 [8978681.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1318-21 [9812896.001]
  • [Cites] Genes Dev. 1997 Mar 15;11(6):701-13 [9087425.001]
  • [Cites] FEBS Lett. 1997 Jun 23;410(1):78-82 [9247127.001]
  • [Cites] Science. 1998 Jan 30;279(5351):707-10 [9445476.001]
  • [Cites] Genes Dev. 1998 Feb 15;12(4):502-13 [9472019.001]
  • [Cites] J Biol Chem. 1998 Sep 11;273(37):24052-6 [9727023.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4240-5 [10200246.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1474-81 [10334533.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):16741-6 [10358014.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):17164-70 [10358073.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1422-37 [10364159.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7421-6 [10377430.001]
  • [Cites] Biochem J. 2005 Jan 15;385(Pt 2):399-408 [15456405.001]
  • [Cites] Mol Cancer Ther. 2005 Feb;4(2):271-9 [15713898.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):977-86 [15956255.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4338-40 [15958615.001]
  • [Cites] Oncogene. 2008 Apr 7;27(16):2258-62 [18391968.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8205-11 [14603261.001]
  • [Cites] J Mol Med (Berl). 1999 Sep;77(9):656-65 [10569203.001]
  • [Cites] Biochem J. 1999 Dec 1;344 Pt 2:427-31 [10567225.001]
  • [Cites] Exp Cell Res. 1999 Nov 25;253(1):100-9 [10579915.001]
  • [Cites] EMBO J. 2000 Jun 1;19(11):2393-8 [10835338.001]
  • [Cites] Cell. 2000 Oct 13;103(2):185-8 [11057891.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39223-30 [11010972.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):245-52 [11231573.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(2):101-10 [11261825.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):15609-15 [11278702.001]
  • [Cites] J Natl Cancer Inst. 2001 May 16;93(10):776-82 [11353788.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5985-91 [11507039.001]
  • [Cites] Science. 2001 Nov 2;294(5544):1102-5 [11691993.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):148-54 [11857399.001]
  • [Cites] Science. 2002 May 31;296(5573):1655-7 [12040186.001]
  • [Cites] Mol Cell. 2002 Jul;10(1):151-62 [12150915.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):648-57 [12172553.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3512-9 [12429642.001]
  • [Cites] Toxicol Sci. 2003 Sep;75(1):74-81 [12805649.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Cell. 2004 Apr 16;117(2):225-37 [15084260.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4394-9 [15231645.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]
  • [Cites] Cancer Res. 1987 Oct 15;47(20):5290-3 [3308076.001]
  • [Cites] Int J Cancer. 1989 Mar 15;43(3):431-5 [2784420.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8212-6 [2122455.001]
  • [Cites] Cell. 1992 Aug 7;70(3):389-99 [1643657.001]
  • [Cites] Cell. 1992 Aug 7;70(3):401-10 [1643658.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1725-32 [8411256.001]
  • [Cites] Nature. 1994 Aug 18;370(6490):527-32 [8052307.001]
  • [Cites] Nature. 1994 Oct 27;371(6500):762-7 [7935836.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5744-8 [7777579.001]
  • [Cites] Breast Cancer Res Treat. 1995 Jul;35(1):133-44 [7612899.001]
  • [Cites] Nature. 1995 Aug 17;376(6541):599-602 [7637810.001]
  • [Cites] Oncogene. 1995 Oct 19;11(8):1639-47 [7478589.001]
  • [Cites] Genes Dev. 1998 Nov 15;12(22):3499-511 [9832503.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15587-91 [9861013.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15653-8 [9861025.001]
  • (PMID = 19291795.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES10595; United States / NIEHS NIH HHS / ES / R01 ES010595-05; United States / NIEHS NIH HHS / ES / P30 ES006639-14; United States / NIEHS NIH HHS / ES / P30 ES06639; United States / NIEHS NIH HHS / ES / P30 ES006639; United States / NIEHS NIH HHS / ES / R01 ES010595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Forkhead Transcription Factors; 0 / FoxO3 protein, mouse; 0 / FoxO4 protein, mouse; 0 / Foxo1 protein, mouse; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS137631; NLM/ PMC4123863
  •  go-up   go-down


45. Seefeld M, El Tarhouny S, Fan AX, Hahn S, Holzgreve W, Zhong XY: Parallel assessment of circulatory cell-free DNA by PCR and nucleosomes by ELISA in breast tumors. Int J Biol Markers; 2008 Apr-Jun;23(2):69-73
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parallel assessment of circulatory cell-free DNA by PCR and nucleosomes by ELISA in breast tumors.
  • OBJECTIVES: In order to assess the potential biomolecules for breast cancer, we analyzed in parallel the levels of cell-free glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and cell-free nucleosomes in serum samples from patients with benign and malignant breast tumors.
  • METHODS: Twenty-three patients with benign breast tumors, 27 patients with breast cancer, and 32 age-matched healthy women were recruited.
  • RESULTS: The levels of cell-free GAPDH were significantly higher in the serum samples of patients with benign and malignant breast tumors than in those of the control group (median 37,966 GE/mL, range 3,802-130,104 versus 11,770 GE/mL, range 2,198-73,522, p=0.035 and median 40,698 GE/mL, range 3,644-192,482 versus 11,770 GE/mL range 2,198-73,522, p=0.001).
  • There was, however, no significant difference between healthy individuals and women with benign breast tumors or breast cancer in terms of nucleosomes determined by ELISA.
  • CONCLUSION: Our data suggest that the cell-free serum GAPDH DNA assayed by quantitative PCR is a better biomarker than nucleosomes assayed by ELISA in patients with breast tumors.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / diagnosis. DNA / blood. Enzyme-Linked Immunosorbent Assay / methods. Nucleosomes. Polymerase Chain Reaction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18629778.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nucleosomes; 9007-49-2 / DNA; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


46. Sato K, Ueda Y, Shimasaki M, Ozaki M, Nitta N, Chada K, Ishikawa Y, Katsuda S: Pleomorphic adenoma (benign mixed tumor) of the breast: a case report and review of the literature. Pathol Res Pract; 2005;201(4):333-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma (benign mixed tumor) of the breast: a case report and review of the literature.
  • We report a case of pleomorphic adenoma (benign mixed tumor) of the breast, which is an extremely rare location for this tumor.
  • Examination of a 55-year-old woman unexpectedly revealed a mass measuring 0.8 cm in diameter in the subareolar region of the right breast.
  • Excisional biopsy was performed, and the tumor histologically showed pleomorphic adenoma composed of duct epithelial cells, myoepithelial cells, and a myxochondroid matrix.
  • Sixty-nine cases of this type of tumor arising in the breast have been described previously.
  • Using imaging procedures, the tumor has occasionally been misdiagnosed as malignant clinically and even pathologically in frozen section diagnosis.
  • Careful diagnosis based on paraffin sections is required to avoid unnecessary aggressive surgery, and pathologists should include pleomorphic adenoma in the differential diagnosis of a demarcated, juxtaareolar, small hard mass.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. HMGA1a Protein / analysis. HMGA2 Protein / analysis. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Middle Aged. Receptors, Estrogen / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991841.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HMGA2 Protein; 0 / Receptors, Estrogen; 124544-67-8 / HMGA1a Protein
  • [Number-of-references] 32
  •  go-up   go-down


47. Hsiao YH, Huang YL, Liang WM, Lin C, Kuo SJ, Chen DR: Characterization of benign and malignant solid breast masses: harmonic versus nonharmonic 3D power Doppler imaging. Ultrasound Med Biol; 2009 Mar;35(3):353-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of benign and malignant solid breast masses: harmonic versus nonharmonic 3D power Doppler imaging.
  • The aim of this study was to compare the diagnostic performance of nonharmonic ultrasound (US) and tissue harmonic imaging (THI) using three-dimensional (3D) power Doppler sonographic technique to classify benign and malignant breast tumors by vascularization.
  • All subjects with one or more breast masses were studied with 3D power Doppler US nonharmonic and harmonic technologies.
  • A total of 97 benign and 86 pathologically proven malignant breast tumor images were analyzed.
  • Three histogram indices, the vascularization index (VI), flow index (FI) and vascularization-flow index (VFI), on both nonharmonic and harmonic images were calculated for the intratumor and for shells with an outside thickness of 3 mm surrounding the breast lesion.
  • A multilayer perception (MLP) neural network classifier used the vascularity indices to determine whether the breast tumors are benign or malignant.
  • ROC curve analysis used overall age, volume, VI, FI and VFI for both intratumor and shells with an outside thickness of 3 mm surrounding the breast lesions in nonharmonic US and THI.
  • In conclusion, the performance of 3D power Doppler US with respect to the characterization of solid breast masses as benign or malignant was not significantly improved with tissue harmonic imaging.
  • [MeSH-major] Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Image Interpretation, Computer-Assisted / methods. Middle Aged. Neovascularization, Pathologic / ultrasonography. Neural Networks (Computer). Ultrasonography, Doppler / methods. Ultrasonography, Mammary / methods. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041173.001).
  • [ISSN] 1879-291X
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Cui Y, Koop EA, van Diest PJ, Kandel RA, Rohan TE: Nuclear morphometric features in benign breast tissue and risk of subsequent breast cancer. Breast Cancer Res Treat; 2007 Jul;104(1):103-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear morphometric features in benign breast tissue and risk of subsequent breast cancer.
  • Certain nuclear morphometric features measured in breast tumor tissue have been shown to predict the prognosis of breast cancer patients.
  • However, the application of these features to predicting risk of breast cancer development has received little attention.
  • We conducted a case-control study to evaluate nuclear morphometric features in benign breast tissue in association with subsequent breast cancer risk.
  • The study was nested within a cohort of 4,888 women with a histopathologic diagnosis of benign breast disease (BBD) and involved 61 cases and 71 controls, amongst whom there were 53 matched case-control sets.
  • Conditional logistic regression models were fitted to assess various measurements of nuclear size and nuclear shape factors in relation to subsequent breast cancer risk.
  • In multivariate analysis, subsequent breast cancer risk was positively associated with a nuclear shape factor that takes the shortest nuclear axis and the longest nuclear axis into consideration simultaneously (highest quartile versus lowest 3 quartiles: odds ratio = 3.07, 95% confidence limits = 1.61, 5.84).
  • In contrast, there was no alteration in subsequent breast cancer risk in association with nuclear size features and other shape factors.
  • In conclusion, our study results suggest that the shape factor that takes both the shortest nuclear axis and the longest nuclear axis into consideration might be of value to predict subsequent development of breast cancer among women with BBD.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microsc Res Tech. 2002 Oct 15;59(2):109-18 [12373721.001]
  • [Cites] Int J Cancer. 2001 Sep 20;95(5):282-5 [11494225.001]
  • [Cites] Histopathology. 2004 Oct;45(4):352-9 [15469473.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;396(1):9-18 [7123847.001]
  • [Cites] J Clin Pathol. 1986 Jun;39(6):603-9 [3722413.001]
  • [Cites] Lab Invest. 1990 Aug;63(2):270-5 [2381167.001]
  • [Cites] Anal Cell Pathol. 1989 Feb;1(1):11-23 [2562217.001]
  • [Cites] Eur J Surg Oncol. 1991 Aug;17(4):350-3 [1874292.001]
  • [Cites] CMAJ. 1992 Nov 15;147(10):1459-76 [1423087.001]
  • [Cites] CMAJ. 1992 Nov 15;147(10):1477-88 [1423088.001]
  • [Cites] Anal Quant Cytol Histol. 1996 Oct;18(5):374-82 [8908309.001]
  • [Cites] Cancer. 1997 Jun 25;81(3):172-9 [9196016.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9 [9731732.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):800-5 [9743304.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]
  • [Cites] Urology. 1999 Jan;53(1):44-9 [9886586.001]
  • [Cites] Dis Colon Rectum. 1999 Mar;42(3):386-92 [10223762.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1999;256(5):257-61 [10392302.001]
  • [Cites] J Pathol. 1999 Feb;187(3):272-8 [10398078.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):768-72 [15824141.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):297-9 [16034016.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3542-8 [10589770.001]
  • [Cites] Pathol Res Pract. 1999;195(11):741-6 [10605693.001]
  • [Cites] Pol J Pathol. 1999;50(4):235-41 [10721263.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):494-9 [11102893.001]
  • [Cites] J Pathol. 2001 Jan;193(1):33-9 [11169513.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):249-59 [11303595.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):836-41 [12766590.001]
  • (PMID = 17061043.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2092407
  •  go-up   go-down


49. Siddiqui MK, Jyoti, Singh S, Mehrotra PK, Singh K, Sarangi R: Comparison of some trace elements concentration in blood, tumor free breast and tumor tissues of women with benign and malignant breast lesions: an Indian study. Environ Int; 2006 Jul;32(5):630-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of some trace elements concentration in blood, tumor free breast and tumor tissues of women with benign and malignant breast lesions: an Indian study.
  • Fifty women residing in and around New Delhi, India and identified to have benign (25 nos.) and malignant (25 nos.) breast lesions were studied for the first time to access the association between environmental exposure to lead and risk of breast cancer and to determine the potential of changes in trace elements concentration as a diagnostic marker and/or its etiological involvement in the disease.
  • Blood, tumor tissue and breast adipose tissue from tumor free area from each patient of the two groups, collected at the time of lumpectomy or mastectomy (only blood sample was collected from disease free control group), were analyzed to determine the concentration of Pb, Zn, Cu, Fe and Ca using Atomic Absorption Spectrometry.
  • Blood lead was significantly higher in malignant cases than in those of benign and control (p<0.05 each).
  • Lead level was also higher in tumor tissue when compared with their respective normal tumor free breast tissue, though non-significant, in both benign and malignant cases.
  • Interestingly, Zn, Fe, and Ca levels were higher in blood of malignant cases than in those of their benign counterparts.
  • Furthermore, these metals were also higher in tumor of malignant and benign cases as compared to normal tumor free breast tissue, many of them statistically significant (p<0.05/0.01/0.001).
  • However, Cu level was insignificantly lower in the blood and tumor tissue of malignant cases when compared with their benign counterparts while it was significantly higher (p<0.05) in tumor of benign cases when compared with those of their respective normal tumor free breast tissue.
  • There were statistically significant correlations between lead and trace element levels only in normal tumor free breast tissue of benign and malignant cases (r=0.41-0.73; p<0.05-0.001) but neither in blood nor tumor tissue of the two groups.
  • These results suggest that in the backdrop of existing experimental and epidemiological evidences exposure to lead may be one of the risk factors for breast lesions; though it warrants further investigation.
  • Further, modulation of trace elements level in both benign and malignant breast diseases patients may be of potential to be used as diagnostic marker of the disease process and its possible relationship etiologically.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Mammary Glands, Human / metabolism. Trace Elements / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580070.001).
  • [ISSN] 0160-4120
  • [Journal-full-title] Environment international
  • [ISO-abbreviation] Environ Int
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Trace Elements
  •  go-up   go-down


50. Valdes EK, Feldman SM, Krassilnik N: Neuroendocrine tumor of the breast. Am Surg; 2006 Feb;72(2):185-7
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumor of the breast.
  • Mammary carcinoid is an uncommon neoplasm.
  • It accounts for approximately 5 per cent of all breast carcinomas.
  • However, it is still controversial whether mammary carcinoid tumors should be considered a distinct clinical entity or be treated as a variant of conventional breast carcinoma.
  • Differentiating these lesions from benign lesions such as epithelial hyperplasia and papillomas can be challenging at times.
  • We present a case of neuroendocrine tumor of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoid Tumor / pathology. Carcinoma, Ductal, Breast / pathology

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536254.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Gönenç A, Erten D, Aslan S, Akinci M, Simşek B, Torun M: Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease. Cell Biol Int; 2006 Apr;30(4):376-80
Hazardous Substances Data Bank. MALONALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease.
  • Changes in the levels of malondialdehyde (MDA), nitrate and nitrite (as an index of nitric oxide production), lipid hydroperoxide (LOH), total antioxidant capacity (TAC), lipids (total cholesterol and triglycerides) and lipoproteins (HDL- and LDL-cholesterol) were estimated in breast cancer patients (n = 15) and benign breast disease (n = 15).
  • Serum and tissue MDA levels were found to be decreased in breast cancer patients compared to the benign group (p < 0.05).
  • In contrast, nitrate and nitrite levels were increased in serum and tissue of the cancer group compared to benign breast disease patients (p < 0.05).
  • Compared to the benign group, tissue TAC levels were elevated in the breast cancer patient group (p < 0.05).
  • Total cholesterol and HDL-cholesterol were elevated in the benign group compared with cancer patients (p < 0.05).
  • These findings support the hypothesis that lipid peroxidation in serum and tissue of benign breast disease is greater than in breast cancer.
  • However, the enhanced levels of nitric oxide may be in response to inflammation in patients with breast cancer.
  • Total antioxidant status is lower in benign tissue than in cancerous tissue, probably to compensate for this elevated free radical production.
  • [MeSH-major] Antioxidants / metabolism. Breast / metabolism. Breast / pathology. Breast Neoplasms / blood. Breast Neoplasms / metabolism. Lipid Peroxidation

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16616293.001).
  • [ISSN] 1065-6995
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Lipid Peroxides; 0 / Nitrates; 0 / Nitrites; 4Y8F71G49Q / Malondialdehyde
  •  go-up   go-down


52. Liebhardt S, Ditsch N, Nieuwland R, Rank A, Jeschke U, Von Koch F, Friese K, Toth B: CEA-, Her2/neu-, BCRP- and Hsp27-positive microparticles in breast cancer patients. Anticancer Res; 2010 May;30(5):1707-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEA-, Her2/neu-, BCRP- and Hsp27-positive microparticles in breast cancer patients.
  • BACKGROUND: This is the first prospective case-control study that evaluates the expression of tumour-specific antigens on circulating microparticles (MP) in breast cancer patients and in women with benign breast tumour.
  • MATERIALS AND METHODS: MP were determined by flow cytometry in patients with breast cancer (n=34; T1 (n=19) and T2 (n=15)) and women with benign breast tumour (n=19).
  • RESULTS: Patients with lymph node metastases (N1, n=9) showed significantly higher numbers of annexin V(+) MP (p=0.042), CD66(+) MP (p=0.045), BCRP1(+) MP (breast cancer resistance protein) (p=0.025) and Hsp27(+) MP (p=0.034) than controls.
  • CONCLUSION: Significant differences are present between breast cancer patients with lymph node metastases and controls concerning annexin V-, CD66-, BCRP1- and Hsp27-positive MP.
  • To specify the role of these MP subpopulations in breast cancer progression, further studies enrolling larger patient groups are part of ongoing research.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Breast Neoplasms / metabolism. Carcinoembryonic Antigen / metabolism. Cell-Derived Microparticles. HSP27 Heat-Shock Proteins / metabolism. Neoplasm Proteins / metabolism. Receptor, ErbB-2 / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592365.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Annexin A5; 0 / Carcinoembryonic Antigen; 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Neoplasm Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


53. Wilke LG, Brown JQ, Bydlon TM, Kennedy SA, Richards LM, Junker MK, Gallagher J, Barry WT, Geradts J, Ramanujam N: Rapid noninvasive optical imaging of tissue composition in breast tumor margins. Am J Surg; 2009 Oct;198(4):566-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid noninvasive optical imaging of tissue composition in breast tumor margins.
  • BACKGROUND: In women undergoing breast conserving surgery (BCS), up to 60% can require re-excision.
  • Our objective is to develop an optically based technology which can differentiate benign from malignant breast tissues intraoperatively through differences in tissue composition factors.
  • Within 34 specimens with pathologically confirmed positive margins, the ratio map of b-carotene/scattering showed the most significant difference reflecting a decrease in adipose and an increase in cell density within malignant margins (p=.002).
  • CONCLUSIONS: We present a novel optical spectral imaging device that provides a rapid, non-destructive assay of the tissue composition of breast tumor margins.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2002 Jul;126(7):846-8 [12088456.001]
  • [Cites] Curr Opin Biotechnol. 2009 Feb;20(1):119-31 [19268567.001]
  • [Cites] Am J Surg. 2002 Nov;184(5):383-93 [12433599.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):697-702 [12910512.001]
  • [Cites] CA Cancer J Clin. 1999 May-Jun;49(3):159-77 [10445015.001]
  • [Cites] Eur J Surg Oncol. 2004 Dec;30(10):1058-64 [15522551.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jan;184(1):324-9 [15615996.001]
  • [Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]
  • [Cites] J Am Coll Surg. 2005 Aug;201(2):194-8 [16038815.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1625-32 [16327435.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2087-106 [16360786.001]
  • [Cites] Appl Opt. 2006 Feb 10;45(5):1062-71 [16512550.001]
  • [Cites] Appl Opt. 2006 Feb 10;45(5):1072-8 [16512551.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Am J Surg. 2006 Oct;192(4):509-12 [16978962.001]
  • [Cites] Am J Surg. 2006 Oct;192(4):538-40 [16978970.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1458-71 [17260108.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2953-60 [17674109.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3133-40 [17653798.001]
  • [Cites] J Am Coll Surg. 2008 Jan;206(1):76-82 [18155571.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1297-303 [18259820.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1271-2 [18320287.001]
  • [Cites] Cancer. 2008 May 1;112(9):1923-31 [18327818.001]
  • [Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024012 [18465975.001]
  • [Cites] J Am Coll Surg. 2008 Jun;206(3):1116-21 [18501808.001]
  • [Cites] J Biomed Opt. 2008 May-Jun;13(3):034015 [18601560.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2542-9 [18618180.001]
  • [Cites] Am J Surg. 2008 Oct;196(4):556-8 [18809063.001]
  • [Cites] World J Surg. 2008 Dec;32(12):2599-606 [18836763.001]
  • [Cites] Eur J Surg Oncol. 2009 Jan;35(1):32-7 [18539425.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jan;113(2):397-402 [18386174.001]
  • [Cites] J Biomed Opt. 2009 Jan-Feb;14(1):014024 [19256712.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1615-20 [19255332.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2919-26 [19293184.001]
  • [Cites] Cancer. 2009 Apr 15;115(8):1669-79 [19170229.001]
  • [Cites] Am J Surg. 2002 Aug;184(2):89-93 [12169349.001]
  • (PMID = 19800470.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024128; United States / NCRR NIH HHS / RR / UL1 RR024128-01; United States / NCRR NIH HHS / RR / 1UL1 RR024128-01
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS137679; NLM/ PMC2764289
  •  go-up   go-down


54. Behera MA, Dai Q, Garde R, Saner C, Jungheim E, Price TM: Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells. Am J Physiol Endocrinol Metab; 2009 Nov;297(5):E1089-96
Hazardous Substances Data Bank. CYCLOHEXIMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells.
  • The effects of progesterone on breast epithelial cells remain poorly defined with observations showing both proliferative and antiproliferative effects.
  • The release of paracrine growth factors from nuclear receptor-positive cells has been postulated as a mechanism, since in vitro studies show a lack of growth effect by progesterone in breast epithelial cells lacking nuclear receptors.
  • This study examined possible nongenomic effects of progesterone in breast epithelia by using MCF-10A cells known to lack nuclear progesterone receptor expression.
  • Our study demonstrates a nongenomic action of progesterone on benign breast epithelial cells, resulting in enhanced cellular respiration and protection from apoptosis.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Cell Cardiol. 1995 Oct;27(10):2167-76 [8576933.001]
  • [Cites] Genes Dev. 1995 Sep 15;9(18):2266-78 [7557380.001]
  • [Cites] Breast Cancer Res Treat. 1997 Sep;45(2):121-33 [9342437.001]
  • [Cites] Exp Cell Res. 1997 Oct 10;236(1):223-30 [9344602.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):4987-91 [9371488.001]
  • [Cites] J Biol Chem. 1999 Apr 30;274(18):12567-75 [10212235.001]
  • [Cites] Breast Cancer Res Treat. 1999 Feb;53(3):217-27 [10369068.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Nov;97(3):278-88 [16154741.001]
  • [Cites] Dev Cell. 2005 Dec;9(6):843-54 [16326395.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Feb;98(2-3):174-8 [16413775.001]
  • [Cites] J Biol Chem. 2006 Mar 3;281(9):5837-44 [16407197.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Mar;98(4-5):218-27 [16466914.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):925-35 [16361271.001]
  • [Cites] Apoptosis. 2006 Apr;11(4):473-85 [16532373.001]
  • [Cites] Biochim Biophys Acta. 2006 May-Jun;1757(5-6):509-17 [16829228.001]
  • [Cites] Maturitas. 2006 Jul 20;54(4):327-34 [16806749.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2006 Nov;129(1):77-83 [16460873.001]
  • [Cites] Mol Endocrinol. 2006 Dec;20(12):3146-64 [16959873.001]
  • [Cites] FEBS J. 2007 Mar;274(6):1393-418 [17302740.001]
  • [Cites] Endocrinology. 2007 Jun;148(6):2723-36 [17332059.001]
  • [Cites] Cell Prolif. 2007 Oct;40(5):721-40 [17877612.001]
  • [Cites] Biol Chem. 2007 Oct;388(10):1113-9 [17937626.001]
  • [Cites] Mitochondrion. 2007 Dec;7(6):399-401 [17881297.001]
  • [Cites] Methods. 2008 Mar;44(3):222-8 [18314052.001]
  • [Cites] Breast. 2008 Apr;17(2):172-9 [17928227.001]
  • [Cites] Cell Res. 2009 Jan;19(1):140-8 [19079362.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Dec;84(12):4559-65 [10599719.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):867-72 [10706096.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):936-43 [10706108.001]
  • [Cites] Oncology. 2000;59 Suppl 1:39-44 [11096355.001]
  • [Cites] Mol Endocrinol. 2001 Feb;15(2):255-70 [11158332.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jun 20;179(1-2):97-103 [11420134.001]
  • [Cites] Endocrinology. 2002 Aug;143(8):3071-82 [12130573.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):93-105 [12160089.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] Breast Cancer Res. 2002;4(5):187-90 [12223122.001]
  • [Cites] Mol Endocrinol. 2003 Jan;17(1):117-27 [12511611.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2231-6 [12574519.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2237-42 [12601167.001]
  • [Cites] Mol Cell Endocrinol. 2003 Feb 28;200(1-2):155-63 [12644308.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):25-30 [12650698.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 23;1658(1-2):141-7 [15282185.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Aug;71(8):2942-5 [4528490.001]
  • [Cites] Nature. 1975 Feb 27;253(5494):746-7 [1113869.001]
  • [Cites] Cancer Res. 1978 Aug;38(8):2434-7 [667841.001]
  • [Cites] Exp Cell Res. 1988 Sep;178(1):143-53 [3409975.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Mol Endocrinol. 1990 Dec;4(12):1833-40 [2082185.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):340-3 [8275464.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3868-77 [8033109.001]
  • [Cites] J Exp Med. 1994 Sep 1;180(3):917-23 [8064240.001]
  • [Cites] Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):123-8 [9024102.001]
  • (PMID = 19690070.001).
  • [ISSN] 1522-1555
  • [Journal-full-title] American journal of physiology. Endocrinology and metabolism
  • [ISO-abbreviation] Am. J. Physiol. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / 1R03HD-052770-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Inhibitor of Differentiation Protein 1; 0 / Protein Synthesis Inhibitors; 0 / Receptors, Progesterone; 0 / Transforming Growth Factor beta1; 4G7DS2Q64Y / Progesterone; 8L70Q75FXE / Adenosine Triphosphate; 98600C0908 / Cycloheximide; EC 3.4.21.- / Kallikreins; EC 3.4.22.- / Caspases; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


55. Jiang YX, Liu H, Liu JB, Zhu QL, Sun Q, Chang XY: Breast tumor size assessment: comparison of conventional ultrasound and contrast-enhanced ultrasound. Ultrasound Med Biol; 2007 Dec;33(12):1873-81
Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast tumor size assessment: comparison of conventional ultrasound and contrast-enhanced ultrasound.
  • Accurate assessment of tumor size is necessary when selecting patients for breast-conserving surgery.
  • In the study of breast contrast-enhanced ultrasound (CEUS), we found that tumor size discrepancy between CEUS and conventional ultrasound (US) existed in some breast lesions, for which the reasons are not clear.
  • Breast CEUS examinations were performed in 104 patients with breast lesions.
  • The measurement of the 104 breast tumors on conventional US was obtained and compared with the measurement on CEUS.
  • A difference in measuring tumor size of >3 mm for tumors up to 1.7 cm and 4 mm for tumors >or=1.7 cm, was defined as a significant discrepancy between conventional US and CEUS.
  • The histopathological examination of size discrepancy was performed and the margin characteristics of breast cancers with larger measurements were compared with those with unchanged measurements.
  • Among the 104 lesions (43 malignant, 60 benign, 1 borderline), the size of 27 breast cancers and one granulomatous mastitis appeared larger at CEUS.
  • Pathologic examinations of the region corresponding to the measurement discrepancy were mainly ductal carcinomas in situ (DCIS), invasive carcinoma with a DCIS component, adenosis with lobular hyperplasia in breast cancers and inflammatory cell infiltration in one granulomatous mastitis.
  • Well-defined margin characteristics were significantly different between breast cancers with larger measurements at CEUS and those with unchanged measurements of size (p = 0.002), whereas no significant difference was found between the two groups in ill-defined, spiculated, hyperechoic halo, microlobulated and angulated margins (p = 0.463, 0.117, 0.194, 0.666 and 0.780, respectively).
  • This initial study suggests that significant discrepancy of breast lesion measurement between conventional US and CEUS is more likely presented in breast cancer than benign lesions.
  • The pathologic findings corresponding to the region of size increased at CEUS are malignant in most malignant lesions and benign in benign lesions.
  • It is difficult to predict whether the size measurement of the breast cancer increases at CEUS based on the margin characteristics showed on conventional US.
  • [MeSH-major] Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Diseases / pathology. Breast Diseases / ultrasonography. Contrast Media. Female. Humans. Image Interpretation, Computer-Assisted / methods. Middle Aged. Neoplasm Staging. Phospholipids. Reproducibility of Results. Sulfur Hexafluoride

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17686569.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


56. Zhu Y, Wang T, Lin J, Li D, Peng Y, Luo Y: [Fast edge extraction for ultrasound image of breast tumor based on fuzzy number]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2006 Jun;23(3):488-91
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fast edge extraction for ultrasound image of breast tumor based on fuzzy number].
  • An accurate edge extraction method for the ultrasound breast tumor image is useful for classifying tumors as benign or malignant.
  • This paper refers to a fast technique to extract edge of breast tumor from ultrasound image.
  • Experiments of benign and malignant breast tumor in ultrasound images have shown that our method can extract the breast tumor edge faster than many conventional methods can do separately, and the results are reliable and credible.
  • Our experiments demonstrate that it can be efficiently used to extract the edge of breast tumor from the ultrasound image.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Ultrasonography, Mammary / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856374.001).
  • [ISSN] 1001-5515
  • [Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
  • [ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


57. Sandhya B, Babu V, Parthasarathy G, Kate V, Ananthakrishnan N, Krishnan R: Primary leiomyosarcoma of the breast: A case report and review of literature. Indian J Surg; 2010 Jul;72(Suppl 1):286-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary leiomyosarcoma of the breast: A case report and review of literature.
  • Leiomyosarcomas of the breast are rare tumours.
  • We describe herein a case of primary leiomyosarcoma of the breast in a 54-year-old woman whose preoperative clinical and cytological findings indicated a benign breast tumour.
  • Histopathological examination of the mastectomy specimen suggested a diagnosis of leiomyosarcoma, which was subsequently confirmed by immunohistochemical analysis.
  • Primary leiomyosarcoma of the breast is very rare and is difficult to diagnose preoperatively as it needs immuno-histochemical staining.
  • It is necessary to excise the tumour with sufficient margins to prevent local recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 1997;27(11):1082-5 [9413066.001]
  • [Cites] Pathol Oncol Res. 2001;7(2):151-3 [11458280.001]
  • [Cites] Surg Today. 2002;32(8):716-9 [12181723.001]
  • [Cites] Arch Gynecol Obstet. 2003 Feb;267(4):233-5 [12592426.001]
  • [Cites] Breast J. 2003 Nov-Dec;9(6):494-6 [14616945.001]
  • [Cites] Diagn Cytopathol. 2003 Sep;29(3):172-8 [12951688.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):783-6 [14526679.001]
  • (PMID = 23133273.001).
  • [ISSN] 0972-2068
  • [Journal-full-title] The Indian journal of surgery
  • [ISO-abbreviation] Indian J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3451846
  • [Keywords] NOTNLM ; Breast / Phyllodes Sandhya / Stromal tumours
  •  go-up   go-down


58. Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, Bürki N, Diesch C, Holzgreve W, Zhong XY: Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer; 2009;8:105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors.
  • METHODS: Using multiplex real-time PCR we investigated the levels of ccf nDNA and mtDNA in plasma samples from patients with malignant and benign breast tumors, and from healthy controls.
  • RESULTS: While the levels of ccf nDNA in the cancer group were significantly higher in comparison with the benign tumor group (P < 0.001) and the healthy control group (P < 0.001), the level of ccf mtDNA was found to be significantly lower in the two tumor-groups (benign: P < 0.001; malignant: P = 0.022).
  • The level of ccf nDNA was also associated with tumor-size (<2 cm vs. >2 cm<5 cm; 2250 vs. 6658; Mann-Whitney-U-Test: P = 0.034).
  • Using ROC curve analysis, we were able to distinguish between the breast cancer cases and the healthy controls using ccf nDNA as marker (cut-off: 1866 GE/ml; sensitivity: 81%; specificity: 69%; P < 0.001) and between the tumor group and the healthy controls using ccf mtDNA as marker (cut-off: 463282 GE/ml; sensitivity: 53%; specificity: 87%; P < 0.001).
  • CONCLUSION: Our data suggests that nuclear and mitochondrial ccf DNA have potential as biomarkers in breast tumor management.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Cell Nucleus / genetics. DNA, Mitochondrial / blood
  • [MeSH-minor] Case-Control Studies. Cell-Free System. Cohort Studies. Diagnosis, Differential. Female. Health. Humans. Lymph Nodes / pathology. Neoplasm Metastasis. ROC Curve. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):905-8 [16900126.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):629-38 [16568452.001]
  • [Cites] BMC Cancer. 2006;6:269 [17116247.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] Mitochondrion. 2007 Feb-Apr;7(1-2):157-63 [17280876.001]
  • [Cites] Mitochondrion. 2007 Feb-Apr;7(1-2):53-7 [17320491.001]
  • [Cites] Acta Paediatr. 2007 May;96(5):644-7 [17376185.001]
  • [Cites] Int J Biol Markers. 2007 Apr-Jun;22(2):95-9 [17549664.001]
  • [Cites] Arch Gynecol Obstet. 2007 Oct;276(4):327-31 [17431649.001]
  • [Cites] Prostate. 2008 Mar 1;68(4):408-17 [18196528.001]
  • [Cites] Clin Chem Lab Med. 2008;46(3):311-7 [18254709.001]
  • [Cites] JAMA. 2008 May 14;299(18):2151-63 [18477782.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):921-5 [18507037.001]
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Jun;16(3):699-703 [18549658.001]
  • [Cites] Int J Biol Markers. 2008 Apr-Jun;23(2):69-73 [18629778.001]
  • [Cites] DNA Cell Biol. 2008 Aug;27(8):415-21 [18694299.001]
  • [Cites] Nat Med. 2008 Sep;14(9):985-90 [18670422.001]
  • [Cites] Obstet Gynecol. 2008 Oct;112(4):843-50 [18827127.001]
  • [Cites] Ann N Y Acad Sci. 2008 Aug;1137:175-9 [18837944.001]
  • [Cites] Cytokine. 2008 Oct;44(1):65-9 [18691902.001]
  • [Cites] Expert Rev Neurother. 2008 Dec;8(12):1841-52 [19086880.001]
  • [Cites] Neuroimage. 2009 Jun;46(2):394-410 [19236926.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1903-6 [11106320.001]
  • [Cites] Lancet. 2001 Jan 27;357(9252):310-1 [11214156.001]
  • [Cites] Swiss Med Wkly. 2001 Feb 10;131(5-6):70-4 [11383228.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;945:138-40 [11708467.001]
  • [Cites] Clin Chim Acta. 2002 Jul;321(1-2):77-87 [12031596.001]
  • [Cites] Int J Gynaecol Obstet. 1995 Feb;48(2):187-92 [7540567.001]
  • [Cites] Lab Invest. 1996 Mar;74(3):592-9 [8600309.001]
  • [Cites] Brain Res Mol Brain Res. 1997 Dec 15;52(2):284-9 [9495550.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):920-4 [15856456.001]
  • [Cites] Tumour Biol. 2005 Nov-Dec;26(6):281-93 [16254457.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1564-9 [16533782.001]
  • [Cites] Prenat Diagn. 2006 Apr;26(4):362-8 [16566058.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1087-91 [17047655.001]
  • (PMID = 19922604.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Mitochondrial; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2780981
  •  go-up   go-down


59. Hu X, Zhang Y, Zhang A, Li Y, Zhu Z, Shao Z, Zeng R, Xu LX: Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology. OMICS; 2009 Aug;13(4):291-300
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology.
  • In the present study, a two-dimensional liquid chromatography-tandem mass spectrometry (2D-LC-MS/MS) on a linear ion trap was utilized to identify and compare serum proteins from breast cancer patients.
  • Three groups of 21 human sera, 7 from patients with lymph node-negative invasive ductal carcinoma (IDCB), 7 from patients with lymph node-positive IDCB, and 7 controls from patients with benign breast diseases, were analyzed.
  • By quantification with label-free spectral counting, a fruitful list of serum proteins with significant differences in abundance accompanying the progression of breast cancer was found.
  • Among the selected proteins, tenascin-XB (TNXB) was further validated by the ELISA method in 131 serum samples as a promising biomarker for early metastasis of breast cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Diseases / pathology. Breast Neoplasms / metabolism. Proteome / analysis. Proteomics / methods

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624269.001).
  • [ISSN] 1557-8100
  • [Journal-full-title] Omics : a journal of integrative biology
  • [ISO-abbreviation] OMICS
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome
  •  go-up   go-down


60. André F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S: Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol; 2009 Apr;10(4):381-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis.
  • BACKGROUND: Gene-expression arrays have generated molecular predictors of relapse and drug sensitivity in breast cancer.
  • We aimed to identify exons differently expressed in malignant and benign breast lesions and to generate a molecular classifier for breast-cancer diagnosis.
  • METHODS: 165 breast samples were obtained by fine-needle aspiration.
  • A nearest centroid prediction rule was developed to classify lesions as malignant or benign on a training set, and its performance was assessed on an independent validation set.
  • A two-way ANOVA model identified probe sets with differential expression in malignant and benign lesions while adjusting for scan dates.
  • FINDINGS: 120 breast cancers and 45 benign lesions were included in the study.
  • A molecular classifier for breast-cancer diagnosis with 1228 probe sets was generated from the training set (n=94).
  • In the validation set (n=71), the molecular predictor accurately classified 68 of 71 tumours (96%, 88-99%).
  • When the 165 samples were taken into account, 37 858 exon probe sets (5.4%) and 3733 genes (7.0%) were differently expressed in malignant and benign lesions (threshold: adjusted p<0.05).
  • In the same population of 165 samples, 956 exon probe sets presented both higher intensity and higher splice index in breast cancer than in benign lesions, although located on unchanged genes.
  • INTERPRETATION: Many exons are differently expressed by breast cancer and benign lesions, and alternative transcripts contribute to the molecular characteristics of breast malignancy.
  • Development of molecular classifiers for breast-cancer diagnosis with fine-needle aspiration should be possible.
  • [MeSH-major] Breast Neoplasms / genetics. Exons / genetics. Gene Expression Profiling. Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Carcinoma, Lobular / secondary. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA Splicing / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. Validation Studies as Topic. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Apr;10(4):314-5 [19341968.001]
  • (PMID = 19249242.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


61. Yao C, Wang SM, Xie D, Wu HX, Chen DY, Lin Y: [The relationship between expression of interleukin-8 and prognosis of breast cancer]. Zhonghua Wai Ke Za Zhi; 2006 Jul 1;44(13):900-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The relationship between expression of interleukin-8 and prognosis of breast cancer].
  • OBJECTIVE: To investigate the expression of interleukin-8 (IL-8) and its prognostic significance in breast cancer.
  • METHODS: Expression of IL-8 in 113 breast cancers, 19 breast benign tumors and 20 breast normal tissues was examined by tissue microarray using immunohistochemistry, and the association of IL-8 expression with patient's clinico-pathological characteristics and prognosis was further analyzed.
  • RESULTS: The positive rate of IL-8 expression in breast cancer was 27.4%, which was significantly higher than that in benign tumor and normal tissue of breast (P = 0.002).
  • CONCLUSIONS: IL-8 might be a poor prognostic factor for human breast cancer, and also might be a novel molecular marker to predicate the occurrence and progression of breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Interleukin-8 / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067482.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


62. Schneider HP, Böcker W: Hormones and progeny of breast tumor cells. Climacteric; 2006 Apr;9(2):88-107
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormones and progeny of breast tumor cells.
  • The rudimentary human glandular breast, with the approach of puberty, starts to grow both at glandular and stromal sites.
  • The risk of breast cancer is inversely related to parity.
  • Women during adolescence have the highest susceptibility to breast cancer development.
  • Immunophenotypia of benign proliferative breast disease favors a fundamentally different epithelial composition from that of most malignant epithelial proliferations such as atypical ductal hyperplasia, ductal carcinoma in situ, lobular neoplasia and invasive breast carcinoma.
  • Immunophenotypical characterization of these lesions assists in distinguishing benign from malignant disease.
  • One should, however, realize that ductal as well as lobular premalignant breast lesions ultimately arise from stem cells in the terminal duct lobular units.
  • Based on our immunocytochemical observations, the most likely target cell of malignant transformation is the Ck18/18-positive and ER-negative transient cell of normal breast epithelium.
  • Pregnancy confers a different genomic imprint to breast epithelial stem cells.
  • Further elucidation of this mechanism may assist in developing appropriate means of breast cancer prevention.
  • This paper is the Pieter van Keep Memorial Lecture given by Professor Hermann Schneider at the 11th World Congress on the Menopause, October 18-22, 2005, in Buenos Aires, Argentina.
  • [MeSH-major] Breast Neoplasms. Cell Transformation, Neoplastic. Mammary Glands, Human / cytology. Mammary Glands, Human / pathology. Neoplastic Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698656.001).
  • [ISSN] 1369-7137
  • [Journal-full-title] Climacteric : the journal of the International Menopause Society
  • [ISO-abbreviation] Climacteric
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens
  • [Number-of-references] 63
  •  go-up   go-down


63. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, Kuznetsova NP, Vlassov VV, Laktionov PP: Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer; 2006 May 22;94(10):1492-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation.
  • Tumour development is characterised by the increased circulating DNA (cirDNA) concentration and by tumour-related changes in blood plasma DNA.
  • Concentration of cirDNA and methylation of RARbeta2, RASSF1A and HIC-1 gene promoters were investigated in cell-free and cell-surface-bound fractions from healthy donors, patients with breast cancer, and patients with breast fibroadenoma.
  • Tumour development was shown to lead to significant changes in the distribution of cirDNA between cell-free and cell-surface-bound fractions.
  • Analysis of RARbeta2 and RASSF1A methylation in the total cirDNA provides 95% diagnostic coverage in breast cancer patients, 60% in patients with benign lesions, and is without false-positive results in healthy women.
  • Results of the study indicate that methylation-specific PCR of RARbeta2 and RASSF1A genes based on the total cirDNA combined with the quantitative analysis of cirDNA distribution between cell-bound and cell-free fractions in blood provide the sensitive and accurate detection and discrimination of malignant and benign breast tumours.
  • [MeSH-major] Breast Neoplasms / blood. DNA Methylation. DNA, Neoplasm / blood. DNA-Binding Proteins / genetics. Fibroadenoma / blood. Receptors, Retinoic Acid / genetics. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2000 Apr;906:5-7 [10818586.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:191-6 [17108211.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):71-6 [11829433.001]
  • [Cites] Anticancer Drugs. 2002 Apr;13(4):353-7 [11984080.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5462-82 [12154408.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):149-52 [12455027.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:217-20 [15251963.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:221-7 [15251964.001]
  • [Cites] Anal Biochem. 1980 Mar 1;102(2):344-52 [6158890.001]
  • [Cites] J Clin Invest. 1985 Dec;76(6):2182-90 [3001145.001]
  • [Cites] Mol Biol (Mosk). 1988 Nov-Dec;22(6):1667-72 [3252155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Nucleic Acids Res. 1999 Jun 1;27(11):2315-24 [10325420.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3956-63 [10339505.001]
  • [Cites] Histol Histopathol. 1999 Oct;14(4):1159-64 [10506932.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(6-7):873-7 [15560075.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):389-94 [10956415.001]
  • (PMID = 16641902.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / HIC1 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta
  • [Other-IDs] NLM/ PMC2361269
  •  go-up   go-down


64. de Moraes Schenka NG, Schenka AA, de Souza Queiroz L, de Almeida Matsura M, Alvarenga M, Vassallo J: p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast? Appl Immunohistochem Mol Morphol; 2006 Mar;14(1):71-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast?
  • The immunohistochemical detection of myoepithelial cells in benign sclerosing lesions of the breast is useful in distinguishing them from tubular carcinoma.
  • The authors assessed the use of p63 and CD10 in the differential diagnosis between benign sclerosing lesions, such as sclerosing adenosis and radial scar, and tubular carcinoma, in comparison to the traditional myoepithelial markers 1A4 and calponin. p63, CD10, 1A4, and calponin were expressed in myoepithelial cells of all benign lesions and were consistently negative in all cases of tubular carcinoma.
  • In conclusion, p63 and CD10 may be used as a complement to 1A4 in distinguishing benign sclerosing lesions from tubular carcinoma of the breast.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540734.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


65. Cîmpean AM, Raica M, Nariţa D: Diagnostic significance of the immunoexpression of CD34 and smooth muscle cell actin in benign and malignant tumors of the breast. Rom J Morphol Embryol; 2005;46(2):123-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic significance of the immunoexpression of CD34 and smooth muscle cell actin in benign and malignant tumors of the breast.
  • PURPOSE: Our aim was to investigate the distribution of CD34 and smooth muscle cell actin positive myofibroblasts in the stroma of the normal mammary gland, benign and malignant tumors.
  • METHODS: Our study included 112 female patients with suspect breast masses obtained by surgery or biopsy.
  • RESULTS: We have found normal breast tissue, sclerosing adenosis, fibroadenomas, fibrocystic diseases, phyllodes tumor, DCIS, ductal invasive, lobular, squamous, medullary, mucinous, and papillary carcinomas.
  • We also found apocrine metaplasia, florid ductal hyperplasia, atypical hyperplasia, papilloma and LCIS associated with the malignant tumors.
  • All the normal breast tissues and most of benign lesions were positive for CD34 and negative for SMA.
  • The exceptions were represented by a case of fibroadenoma and the phyllodes tumor, with CD34 positivity and a focal acquisition of SMA; fibrocystic disease with associated apocrine metaplasia adjacent to a squamous carcinoma with loss of CD34 expression and focal acquisition of SMA.
  • CONCLUSIONS: Although there were some exceptions especially when one of the two markers was interpreted separately and in some cases associated with sclerotic stroma, we conclude that the combined expression of CD34 and a-SMA is of potential diagnostic value in the distinction between benign and malignant tumors in some difficult cases.
  • [MeSH-major] Actins / analysis. Antigens, CD34 / analysis. Breast Neoplasms / pathology. Muscle, Smooth / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Biopsy. Carcinoma, Ductal / pathology. Female. Fibrocystic Breast Disease / pathology. Humans. Middle Aged. Neoplasm Invasiveness. Smad Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286998.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Smad Proteins
  •  go-up   go-down


66. Porter GJ, Evans AJ, Lee AH, Hamilton LJ, James JJ: Unusual benign breast lesions. Clin Radiol; 2006 Jul;61(7):562-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual benign breast lesions.
  • The purpose of this article is to show examples of the radiological (mammography and/or ultrasound) and pathological appearances of unusual benign breast lesions.
  • The conditions covered are granular cell tumours, fibromatosis, nodular fasciitis, myofibroblastomas, haemangiomas, neurofibromas, and leiomyomas.
  • [MeSH-major] Breast Neoplasms / radiography. Breast Neoplasms / ultrasonography
  • [MeSH-minor] Fasciitis / radiography. Fasciitis / ultrasonography. Female. Fibroma / radiography. Fibroma / ultrasonography. Granular Cell Tumor / radiography. Granular Cell Tumor / ultrasonography. Hemangioma / radiography. Hemangioma / ultrasonography. Humans. Leiomyoma / radiography. Leiomyoma / ultrasonography. Mammography / methods. Neoplasms, Muscle Tissue / radiography. Neoplasms, Muscle Tissue / ultrasonography. Neurofibroma / radiography. Neurofibroma / ultrasonography. Ultrasonography, Mammary / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784941.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 26
  •  go-up   go-down


67. Kukreti S, Cerussi AE, Tanamai W, Hsiang D, Tromberg BJ, Gratton E: Characterization of metabolic differences between benign and malignant tumors: high-spectral-resolution diffuse optical spectroscopy. Radiology; 2010 Jan;254(1):277-84
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of metabolic differences between benign and malignant tumors: high-spectral-resolution diffuse optical spectroscopy.
  • PURPOSE: To develop a near-infrared spectroscopic method to identify breast cancer biomarkers and to retrospectively determine if benign and malignant breast lesions could be distinguished by using this method.
  • By using self-referencing differential spectroscopy (SRDS) analysis, the existence of specific spectroscopic signatures of breast lesions on images acquired by using diffuse optical spectroscopy imaging in the wavelength range (650-1000 nm) was established.
  • There were 17 patients with benign breast tumors and 22 patients with malignant breast tumors.
  • RESULTS: Discrimination analysis helped separate malignant from benign tumors.
  • A total of 40 lesions (22 malignant and 18 benign) were analyzed.
  • CONCLUSION: The SRDS method revealed localized tumor biomarkers specific to pathologic state.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photochem Photobiol. 2000 Sep;72(3):383-91 [10989610.001]
  • [Cites] Breast Cancer Res Treat. 2007 Sep;104(3):249-55 [17051424.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1016-22 [11308247.001]
  • [Cites] Magn Reson Med. 2001 Jun;45(6):994-1000 [11378876.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jul;68(1):45-54 [11678308.001]
  • [Cites] J Biomed Opt. 2002 Jan;7(1):60-71 [11818013.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1197-203 [12189222.001]
  • [Cites] Magn Reson Med. 2003 Dec;50(6):1134-43 [14648561.001]
  • [Cites] Breast. 2003 Jun;12(3):179-82 [14659324.001]
  • [Cites] J Biomed Opt. 2004 Jan-Feb;9(1):230-8 [14715078.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):464-73 [15189083.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):541-52 [15189092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6468-73 [9177241.001]
  • [Cites] Radiology. 1998 Oct;209(1):269-75 [9769842.001]
  • [Cites] J Magn Reson Imaging. 1999 Aug;10(2):159-64 [10441019.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3A):1737-46 [10470108.001]
  • [Cites] Radiology. 2004 Nov;233(2):424-31 [15516615.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):263-70 [15799826.001]
  • [Cites] Med Phys. 2005 Apr;32(4):1128-39 [15895597.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2451-68 [15901948.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):934-47 [16023382.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):925-33 [16023383.001]
  • [Cites] J Lipid Res. 2005 Sep;46(9):1983-90 [15961785.001]
  • [Cites] Radiology. 2005 Oct;237(1):57-66 [16183924.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):051503 [16292947.001]
  • [Cites] Br J Cancer. 2006 Feb 13;94(3):427-35 [16465174.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S302-5 [16507398.001]
  • [Cites] J Magn Reson Imaging. 2006 Aug;24(2):325-32 [16786567.001]
  • [Cites] J Biomed Opt. 2006 Jul-Aug;11(4):044005 [16965162.001]
  • [Cites] Expert Rev Med Devices. 2007 Jan;4(1):83-95 [17187474.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4014-9 [17360469.001]
  • [Cites] J Biomed Opt. 2007 Mar-Apr;12(2):020509 [17477706.001]
  • [Cites] Radiology. 2001 Jan;218(1):261-6 [11152812.001]
  • (PMID = 20032159.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA142989; United States / NCI NIH HHS / CA / U54 CA136400-01; None / None / / P41 RR001192-31; United States / NCI NIH HHS / CA / R01 CA142989-01; United States / NCRR NIH HHS / RR / P41 RR001192-31; United States / NIBIB NIH HHS / EB / R01 EB000559; United States / NCI NIH HHS / CA / U54 CA136400-02; United States / NCI NIH HHS / CA / U54 CA105480-05; United States / NCI NIH HHS / CA / U54 CA105480; United States / NCI NIH HHS / CA / U54 CA136400; United States / NCI NIH HHS / CA / R01 CA142989-02; United States / NCI NIH HHS / CA / P30-CA62203; United States / NCRR NIH HHS / RR / P41 RR003155; United States / NCRR NIH HHS / RR / P41 RR001192; United States / NCI NIH HHS / CA / P30 CA062203; United States / NCRR NIH HHS / RR / P41-RR01192
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2797652
  •  go-up   go-down


68. Williams MB, Judy PG, Gunn S, Majewski S: Dual-modality breast tomosynthesis. Radiology; 2010 Apr;255(1):191-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual-modality breast tomosynthesis.
  • PURPOSE: To evaluate the clinical performance of a hybrid scanner that uses dual-modality tomosynthesis (DMT) and technetium 99m sestamibi to provide coregistered anatomic and functional breast images in three dimensions.
  • MATERIALS AND METHODS: A prospective pilot evaluation of the scanner was performed in women scheduled to undergo breast biopsy after institutional review board approval and informed consent were obtained.
  • RESULTS: Of the 21 lesions, seven were malignant, and 14 were benign.
  • CONCLUSION: Pilot clinical evaluation of the DMT scanner suggests that it is a feasible and accurate method with which to detect and diagnose breast cancer.
  • Systems such as the DMT scanner that are designed specifically for three-dimensional multimodality breast imaging could make possible some of the advances in tumor detection, localization, and characterization of breast cancer that are now being observed with whole-body three-dimensional hybrid systems, such as positron emission tomography/computed tomography (CT) or single photon emission computed tomography/CT.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2010
  • [Cites] Med Phys. 1999 Nov;26(11):2273-85 [10587208.001]
  • [Cites] Breast J. 2007 Sep-Oct;13(5):465-9 [17760667.001]
  • [Cites] J Nucl Med. 2001 Jan;42(1):3-8 [11197976.001]
  • [Cites] Ann Intern Med. 2002 Sep 3;137(5 Part 1):347-60 [12204020.001]
  • [Cites] Ann Intern Med. 2003 Feb 4;138(3):168-75 [12558355.001]
  • [Cites] Technol Cancer Res Treat. 2002 Feb;1(1):39-42 [12614175.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jun;180(6):1675-9 [12760942.001]
  • [Cites] Phys Med Biol. 2003 Oct 7;48(19):R65-106 [14579853.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3B):1631-4 [9179208.001]
  • [Cites] J Nucl Med. 1998 Mar;39(3):449-53 [9529290.001]
  • [Cites] Eur J Nucl Med. 1998 Apr;25(4):375-85 [9553167.001]
  • [Cites] Acad Radiol. 2005 Mar;12(3):286-90 [15766687.001]
  • [Cites] Technol Cancer Res Treat. 2005 Jun;4(3):265-73 [15896082.001]
  • [Cites] Radiology. 2005 Oct;237(1):274-80 [16126919.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):414-22 [16646006.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2007;2007:1335-8 [18002210.001]
  • [Cites] J Natl Cancer Inst. 2008 Jun 18;100(12):876-87 [18544742.001]
  • [Cites] Med Phys. 2008 Jun;35(6):2414-23 [18649474.001]
  • [Cites] Am J Surg. 2008 Oct;196(4):470-6 [18723155.001]
  • [Cites] AJR Am J Roentgenol. 2008 Dec;191(6):1805-15 [19020253.001]
  • [Cites] AJR Am J Roentgenol. 2009 Feb;192(2):379-83 [19155397.001]
  • [Cites] Am J Surg. 2009 Feb;197(2):159-63 [19185109.001]
  • [Cites] Radiology. 2009 Jun;251(3):673-82 [19474373.001]
  • [Cites] J Nucl Med. 2009 Sep;50(9):1401-8 [19690029.001]
  • [Cites] Phys Med Biol. 2006 Oct 7;51(19):5051-64 [16985287.001]
  • [Cites] Neuroimaging Clin N Am. 2006 Nov;16(4):575-89, viii [17148020.001]
  • [Cites] Phys Med Biol. 2007 Feb 7;52(3):603-16 [17228108.001]
  • [Cites] Oncology. 2006;70(6):403-10 [17237619.001]
  • [Cites] J BUON. 2006 Jan-Mar;11(1):61-8 [17318954.001]
  • [Cites] Acad Radiol. 2007 Aug;14(8):945-50 [17659240.001]
  • [Cites] Q J Nucl Med. 2000 Jun;44(2):168-85 [10967626.001]
  • (PMID = 20308457.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069452; United States / NCI NIH HHS / CA / R01 CA 69452
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  • [Other-IDs] NLM/ PMC2843832
  •  go-up   go-down


69. Yamamoto H, Okumura K, Toshima S, Mukaisho K, Sugihara H, Hattori T, Kato M, Asano S: FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues. Biol Pharm Bull; 2009 Jul;32(7):1148-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues.
  • FXYD3, also known as Mat-8 (Mammary tumor 8 kDa), is one of mRNAs highly expressed in mouse and human breast cancers.
  • Here, we newly found that FXYD3 protein was also overexpressed in human breast cancer specimens; invasive ductal carcinomas and intra-ductal carcinomas, whereas its expression was low in benign lesion specimens; mastopathy, fibroadenoma and phyllodes tumors.
  • Here, we found that FXYD3a mRNA is a major transcript product expressed in human normal tissues as well as in breast, colon, stomach and pancreas cancer cell lines.
  • Cell proliferation rate of MCF-7 breast cancer cell line was drastically decreased when FXYD3a and 3b mRNAs were suppressed by the small interfering RNA.
  • These results suggest that FXYD3a protein is highly expressed in breast cancers, and responsible for cancer cell proliferation.
  • [MeSH-major] Breast Neoplasms / metabolism. Cell Proliferation. Membrane Proteins / biosynthesis. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Blotting, Western. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Middle Aged. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction. Sequence Alignment. Transfection

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19571376.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / FXYD3 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


70. García-Reyna JC, Rico Martínez G, Vega González IF, Linares LM, Delgado Cedillo EA, Romero Ramírez R: [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin]. Acta Ortop Mex; 2008 Nov-Dec;22(6):390-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin].
  • [Transliterated title] 99mTc-Tetrofosmin en la evaluación de tumores musculoesqueléticos.
  • INTRODUCTION: (99m)Tc-tetrofosmin is an efficient agent as a tumor marker.
  • Several studies have proven its efficiency in detection and localization of tumors of the breast, larynx, thyroid, parathyroid glands, lung, brain, skin, lymphatic and musculoskeletal tissues with a sensitivity and specificity of 95% to 100%.
  • Nevertheless, benign pathology such as active inflammation is a source of false positives and the attending physician must consider the aid of complementary studies such as histopathology.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Muscle Neoplasms / radionuclide imaging. Organophosphorus Compounds. Organotechnetium Compounds. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280840.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


71. Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P, Benign Breast Diseases Study Group: Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci U S A; 2008 Sep 23;105(38):14533-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
  • Given the essential role of this hormonal system in breast physiology, we reasoned that genetic anomalies of Prl/PrlR genes may be related to the occurrence of breast diseases with high proliferative potential.
  • Multiple fibroadenomas (MFA) are benign breast tumors which appear most frequently in young women, including at puberty, when Prl has well-recognized proliferative actions on the breast.
  • Constitutive activity of PrlR(I146L) in the breast sample from a patient was supported by increased STAT5 signaling.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Fibroadenoma / genetics. Fibroadenoma / metabolism. Mutation, Missense. Receptors, Prolactin / genetics. Receptors, Prolactin / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):665-71 [14696092.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4056-66 [16809439.001]
  • [Cites] Curr Med Res Opin. 2004 Apr;20(4):533-40 [15119991.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2053-60 [15169792.001]
  • [Cites] Acta Obstet Gynecol Scand. 1987;66(6):483-8 [3321867.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4031-5 [7537382.001]
  • [Cites] Mol Endocrinol. 1996 Jan;10(1):45-56 [8838144.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):29707-14 [8939904.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):667-74 [9467590.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):325-35 [16900392.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):571-81 [17024156.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):989-1008 [17138649.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):841-4 [17299388.001]
  • [Cites] BMC Med Genet. 2007;8:72 [18053149.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):41-53 [18246319.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4664-74 [12879011.001]
  • [Cites] Front Biosci. 2000 Mar 1;5:D343-52 [10704433.001]
  • [Cites] Nat Struct Biol. 2000 Sep;7(9):808-15 [10966654.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3826-32 [11502819.001]
  • [Cites] J Endocrinol. 2001 Oct;171(1):R1-4 [11572805.001]
  • [Cites] J Clin Pathol. 2001 Dec;54(12):956-60 [11729217.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):49-66 [12160086.001]
  • [Cites] Endocrine. 2003 Feb-Mar;20(1-2):177-90 [12668884.001]
  • [Cites] Recent Prog Horm Res. 2003;58:297-323 [12795425.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):35988-99 [12824168.001]
  • [Cites] Endocr Rev. 1998 Jun;19(3):225-68 [9626554.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10024-34 [10187780.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):629-34 [10203283.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):275-85 [16034013.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):555-62 [16278261.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1513-9 [16434456.001]
  • [Cites] J Endocrinol. 2006 Aug;190(2):271-85 [16899561.001]
  • [Cites] Biol Reprod. 2004 Mar;70(3):718-28 [14613905.001]
  • (PMID = 18779591.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Receptors, Prolactin; 0 / STAT5 Transcription Factor; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide
  • [Other-IDs] NLM/ PMC2567233
  • [Investigator] Bachelot A; Belaroussi B; Bensimhon J; Berdah J; Blin MJ; Boudinet A; Brethon B; Bricaire C; Caby J; Caillaud G; Carel JC; Chabbert-Buffet N; Charitanski H; Chretien C; Clough K; Courtillot C; Delattre G; Denys I; Desthieux-Ngo K; Detoeuf M; Dhainault C; Duflos C; Fiori O; Genestie C; Gibaud G; Gompel A; Gracia C; Grimard A; Hofman C; Hofman H; Kuttenn F; Laki F; Lanty C; Lefranc JP; Le Frere-Belda MA; Leger D; Martinez F; May A; Meng L; Nos C; Pelletier D; Perrin A; Plu-Bureau G; Raccah-Tebbeca B; Saiovici JC; Salmon R; Sibout M; Sigal-Zafrani B; Thalabard JC; Thibaud E; Thoury A; Touraine P; Triana-Rabi KB; Uzan S; Viriot J; Yacoub S
  •  go-up   go-down


72. Yagata H, Nakamura S, Toi M, Bando H, Ohno S, Kataoka A: Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan. Int J Clin Oncol; 2008 Jun;13(3):252-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan.
  • BACKGROUND: With the development of the CellSearch System, it has become possible to measure circulating tumor cell (CTC) levels with high reproducibility, and the CTC test is currently being used clinically for patients with metastatic breast cancer in the United States.
  • METHODS: Using the CellSearch System, CTC levels were evaluated in 57 healthy individuals and patients with benign breast disease; 30 patients with primary breast cancer (stages 1-3); and 38 patients with metastatic breast cancer.
  • Then, the patients with metastatic breast cancer were divided into two groups, using a cutoff score of 5 CTCs per 7.5 ml blood, and progression-free survival (PFS) and overall survival (OS) were compared in the two groups.
  • RESULTS: When the clinical cutoff score was set at 2 CTCs per 7.5 ml blood, 0% of the healthy individuals and patients with benign breast disease (0/57), 3.3% of the patients with primary breast cancer (1/30), and 50% of the patients with metastatic breast cancer (19/38) were identified as as having 2 CTCs per 7.5 ml blood.
  • CONCLUSION: As concluded in a similar clinical trial in the United States, for patients with breast cancer, measuring CTC levels can be both an accurate indicator of metastases and an important measure of patient prognosis.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Adult. Aged. Cell Count. Cell Separation / instrumentation. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Metastasis. Survival Rate. Tumor Burden

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18553236.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


73. Barra Ade A, Gobbi H, de L Rezende CA, Gouvêa AP, de Lucena CE, Reis JH, Costa e Silva SZ: A comparision of aspiration cytology and core needle biopsy according to tumor size of suspicious breast lesions. Diagn Cytopathol; 2008 Jan;36(1):26-31
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparision of aspiration cytology and core needle biopsy according to tumor size of suspicious breast lesions.
  • The purpose of the study was to compare the accuracy of FNAC, CNB, and combined biopsy according to tumor size of suspicious breast lesions.
  • FNAC and CNB were performed in 264 patients with suspicious breast lesions from August, 1997 to August, 2002.
  • The lesions were divided in four groups according to the tumor size in the histopathology report: lesions smaller than 1 cm, between 1 and 2 cm, between 2 and 5 cm, and lesions greater than 5 cm.
  • The final surgical histopatology results identified 222 (84%) malignant cases and benign lesions summed 42 (16%).
  • The combination of FNAC and CNB can improve the diagnosis of suspicious breast lesions higher than 1 cm.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Biopsy, Needle / methods. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology
  • [MeSH-minor] Breast / pathology. Female. Humans. Predictive Value of Tests. Sensitivity and Specificity. Ultrasonography, Mammary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064684.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Heyer H, Ohlinger R, Schimming A, Schwesinger G, Grunwald S: Parenchymal leiomyoma of the breast--clinical, sonographic, mammographic and histological features. Ultraschall Med; 2006 Feb;27(1):55-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parenchymal leiomyoma of the breast--clinical, sonographic, mammographic and histological features.
  • BACKGROUND: Intraparenchymal leiomyomas of the breast are quite rare.
  • The clinical, mammographic and sonographic characteristics of an intraparenchymal leiomyoma of the breast were evaluated.
  • After surgery, the diagnosis was confirmed histologically.
  • RESULTS: The clinical presentation of our patient with deep-seated leiomyoma of the breast included skin dimpling and a reduction in tissue mobility, differing from more commonly reported characteristics.
  • On breast ultrasonography, the leiomyoma appeared as a hypodense, well demarcated, inhomogeneous lesion with posterior acoustic shadowing.
  • A central tumour vessel was visible on Doppler imaging, and Cooper's ligaments were discontinuous.
  • Acoustic shadowing, the hypodense character, hyperechoic border and the central tumour vessel are therefore additional ultrasonographic characteristics of an intraparenchymal leiomyoma of the breast.
  • CONCLUSION: On breast ultrasonography, an intraparenchymal leiomyoma of the breast can present with posterior acoustic shadowing, hypodense echogenicity, a hyperechoic border and a central tumour vessel.
  • Neither imaging studies nor palpation allow distinction between benign and malignant lesions.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Leiomyoma / ultrasonography
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy. Female. Humans. Mammography. Middle Aged. Mitosis. Palpation. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16470480.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


75. Goel NB, Knight TE, Pandey S, Riddick-Young M, de Paredes ES, Trivedi A: Fibrous lesions of the breast: imaging-pathologic correlation. Radiographics; 2005 Nov-Dec;25(6):1547-59
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibrous lesions of the breast: imaging-pathologic correlation.
  • Fibroepithelial lesions of the breast are commonly seen in clinical practice.
  • Fibroadenomas, benign lesions that derive from the terminal duct lobular unit, are the most common and are often identified at clinical examination or mammography as circumscribed masses.
  • Benign mesenchymal tumors include focal fibrosis, pseudoangiomatous stromal hyperplasia, and fibromatosis or desmoid tumor.
  • Phyllodes tumor, which is similar to fibroadenoma but has increased cellularity in the stroma, is typically benign but has malignant potential.
  • Except for fibromatosis and phyllodes tumor, fibroepithelial lesions need not be excised if the diagnosis is confirmed by the results of histologic analysis at percutaneous biopsy.
  • To correctly differentiate between fibrous breast lesions that are benign and those that should be resected, the physician must be familiar with the correlated radiologic-pathologic findings in the various lesion types.
  • [MeSH-major] Breast / pathology. Breast Diseases / diagnosis. Breast Neoplasms / diagnosis. Neoplasms, Fibroepithelial / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Fibrosis / diagnosis. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2005.
  • (PMID = 16284134.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Mizukami Y, Takayama T, Takemura A, Ichikawa K, Onoguchi M, Miyati T, Taniya T: Pleomorphic adenoma of the breast. Radiat Med; 2008 Aug;26(7):442-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma of the breast.
  • Pleomorphic adenoma is a very rare benign tumor of the breast.
  • Recently, we encountered a case of pleomorphic adenoma of the breast and thus present here the mammographic and ultrasonographic findings with the pathology of this rare breast tumor.
  • The patient was a 76-year-old Japanese woman with a right breast mass.
  • Awareness of this type of tumor will help in correct diagnosis, in spite of the rarity of this disease.
  • [MeSH-major] Adenoma, Pleomorphic / diagnosis. Breast Neoplasms / diagnosis
  • [MeSH-minor] Aged. Breast / surgery. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mammography / methods. Rare Diseases. Treatment Outcome. Ultrasonography, Mammary / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18770004.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


77. El Tarhouny S, Seefeld M, Fan AX, Hahn S, Holzgreve W, Zhong XY: Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor. Cytokine; 2008 Oct;44(1):65-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor.
  • We wanted to find out whether VEGF, VEGFR1 or cfDNA is a biomarker for breast cancer.
  • METHODS: In this study, we used enzyme-linked immunosorbent assay (ELISA) to examine the levels of serum VEGF and VEGFR1 in 23 patients with benign tumors, 19 patients with breast cancer and 32 age-matched healthy females.
  • RESULTS: In terms of serum levels of either VEGF or its soluble receptors VEGFR1, we found no significant difference between healthy individuals and women with benign breast tumors and breast cancer.
  • However, there was a significant increase in circulating cell-free DNA in women with both benign and malignant breast tumors when compared with the corresponding healthy control group.
  • CONCLUSIONS: We can conclude that quantitative analysis of circulating cell-free DNA in serum may provide molecular biological understanding of breast tumors in women.
  • [MeSH-major] Breast Neoplasms / blood. DNA / blood. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor Receptor-1 / blood
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691902.001).
  • [ISSN] 1096-0023
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 9007-49-2 / DNA; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


78. Pereira WC, Alvarenga AV, Infantosi AF, Macrini L, Pedreira CE: A non-linear morphometric feature selection approach for breast tumor contour from ultrasonic images. Comput Biol Med; 2010 Nov-Dec;40(11-12):912-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A non-linear morphometric feature selection approach for breast tumor contour from ultrasonic images.
  • Ultrasound breast images have been used to improve diagnostics and decrease the number of unneeded biopsies.
  • Malignant breast tumors tend to present irregular and blurred contours while benign ones are usually round, smooth and well-defined.
  • Accordingly, investigating the tumor contour may help in establishing diagnosis.
  • Herein, Mutual Information and Linear Discriminant Analysis were implemented to rank morphometric features in discriminating breast tumors in ultrasound images.
  • [MeSH-major] Breast Neoplasms / ultrastructure. Image Enhancement / methods. Ultrasonography, Mammary / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20979993.001).
  • [ISSN] 1879-0534
  • [Journal-full-title] Computers in biology and medicine
  • [ISO-abbreviation] Comput. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


79. Abdallah A, Saklaoui O, Stückle C, Sommerer F, Hatzmann W, Audretsch W, Wesemann A, Zink M, Skoljarev L, Papadopoulos S: [Case reports of operative management of very large, benign phylloid tumors--is a safety margin necessary?]. Gynakol Geburtshilfliche Rundsch; 2009;49(4):320-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case reports of operative management of very large, benign phylloid tumors--is a safety margin necessary?].
  • The phylloid tumor (PT, formerly called cystosarcoma phylloides) is a rare neoplasia of the female breast.
  • Usually the PT is treated with breast-conserving surgery.
  • In spite of progress in early diagnosis, PTs recur frequently--independently of tumor's degree of malignancy.
  • Especially in cases of malignant PT, complete resection with tumor-free margins is seen as the only predictive marker for tumor recurrence or metastases.
  • Benign PT is also often resected with wide tumor-free margins.
  • Because of the tumor's occasionally enormous dimensions, this therapy concept makes breast-conserving surgery almost impossible.
  • A simple enucleation of benign PT is an option to facilitate the preservation of breast tissue and a cosmetically satisfactory breast reconstruction.
  • In the case of particularly large benign PT, enucleation even without wide margins prevents tumor recurrence.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy, Subcutaneous / methods. Phyllodes Tumor / surgery
  • [MeSH-minor] Adult. Biopsy, Needle. Breast / pathology. Esthetics. Female. Follow-Up Studies. Humans. Mammaplasty / methods. Mammography. Middle Aged. Ultrasonography, Mammary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530948.001).
  • [ISSN] 1423-0011
  • [Journal-full-title] Gynäkologisch-geburtshilfliche Rundschau
  • [ISO-abbreviation] Gynakol Geburtshilfliche Rundsch
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


80. Veltman J, Mann R, Kok T, Obdeijn IM, Hoogerbrugge N, Blickman JG, Boetes C: Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI. Eur Radiol; 2008 May;18(5):931-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI.
  • Thus, 29 BRCA-MCs with breast cancer were retrospectively evaluated and the results compared with an age, tumor size and tumor type matched control group of 29 sporadic breast cancer cases.
  • Tumors were analyzed on morphology, density (mammography), enhancement pattern and kinetics (MRI).
  • Malignant lesions in BRCA-MC frequently have morphological characteristics commonly seen in benign lesions, like a rounded shape or sharp margins.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Genes, BRCA1. Genes, BRCA2. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2007 Aug 11;370(9586):485-92 [17693177.001]
  • [Cites] Breast Cancer Res Treat. 2007 May;102(3):357-63 [17051427.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 5;92(13):1081-7 [10880551.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):331-7 [11224603.001]
  • [Cites] N Engl J Med. 2001 Jul 19;345(3):159-64 [11463009.001]
  • [Cites] Eur Radiol. 2001;11(9):1645-50 [11511885.001]
  • [Cites] N Engl J Med. 2002 May 23;346(21):1609-15 [12023992.001]
  • [Cites] Int J Cancer. 2002 Nov 1;102(1):91-5 [12353239.001]
  • [Cites] Radiology. 2002 Oct;225(1):165-75 [12355001.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):296-300 [12559863.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Sep;21(3 Suppl):89-95 [12585661.001]
  • [Cites] Eur Radiol. 2003 Nov;13 Suppl 3:N28-36 [15015878.001]
  • [Cites] Cancer. 2004 May 15;100(10):2079-83 [15139048.001]
  • [Cites] N Engl J Med. 2004 Jul 29;351(5):427-37 [15282350.001]
  • [Cites] Eur Radiol. 2004 Sep;14(9):1647-53 [15083333.001]
  • [Cites] Clin Radiol. 2004 Oct;59(10):895-902 [15451348.001]
  • [Cites] Radiology. 1992 Sep;184(3):623-7 [1324506.001]
  • [Cites] Mayo Clin Proc. 1993 May;68(5):454-60 [8479209.001]
  • [Cites] Radiology. 1994 Feb;190(2):485-93 [8284404.001]
  • [Cites] Lancet. 1994 Mar 19;343(8899):692-5 [7907678.001]
  • [Cites] Radiology. 1994 Aug;192(2):439-42 [8029411.001]
  • [Cites] N Engl J Med. 1997 May 15;336(20):1416-21 [9145678.001]
  • [Cites] Radiology. 1999 Apr;211(1):101-10 [10189459.001]
  • [Cites] Lancet. 2005 May 21-27;365(9473):1769-78 [15910949.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8469-76 [16293877.001]
  • [Cites] Radiology. 2006 Jan;238(1):42-53 [16373758.001]
  • [Cites] JAMA. 2006 May 24;295(20):2374-84 [16720823.001]
  • [Cites] Eur Radiol. 2006 Dec;16(12):2842-8 [16924440.001]
  • [Cites] Radiology. 2007 Mar;242(3):698-715 [17244718.001]
  • [Cites] Eur Radiol. 2007 Apr;17(4):873-87 [17008989.001]
  • [Cites] Radiology. 2000 Apr;215(1):267-79 [10751498.001]
  • (PMID = 18270717.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ PMC2292493
  •  go-up   go-down


81. Lv S, Niu Y, Wei L, Liu Q, Wang X, Chen Y: Chromosomal aberrations and genetic relations in benign, borderline and malignant phyllodes tumors of the breast: a comparative genomic hybridization study. Breast Cancer Res Treat; 2008 Dec;112(3):411-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations and genetic relations in benign, borderline and malignant phyllodes tumors of the breast: a comparative genomic hybridization study.
  • Phyllodes tumors are not quite rare fibroepithelial neoplasms of the breast that show a broad spectrum of clinical behaviour.
  • The molecular genetic features of the heterogenous groups of neoplasms have not been studied in detail yet.
  • We have used comparative genomic hybridization to analyze chromosomal copy number changes in 36 cases of phyllodes tumors (including benign, borderline and malignant phyllodes tumors, 12 cases each).
  • The average number of chromosome copy changes (range) in benign, borderline and malignant phyllodes tumors were 5.58 (0-20), 14.08 (3-23), and 12.42 (0-29) respectively.
  • In benign phyllodes tumors the number of gains and losses was in balance (2.50 vs 3.08), while in borderline and malignant phyllodes tumors gains occurred more often than losses (9.25 vs 4.83, 9.5 vs 2.92).
  • The result suggests the molecular cytogenetics of borderline and malignant phyllodes tumors is similar, and the most striking difference with benign phyllodes tumors is an increased number of chromosomal gains in a nonrandom distribution.
  • Gains of 4q12 seem especially to be involved in the progression of benign to borderline and malignant phyllodes tumors, possibly because of overexpression of oncogenes at these loci.
  • [MeSH-major] Breast Neoplasms / genetics. Chromosome Aberrations. Nucleic Acid Hybridization. Phyllodes Tumor / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18189161.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


82. Ezeome ER, Okafor OC, Nwajiobi CE, Osuagwu CC: Bilateral benign phyllodes tumour in a nulliparous woman: a case report and review of literature. Niger J Clin Pract; 2007 Mar;10(1):66-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral benign phyllodes tumour in a nulliparous woman: a case report and review of literature.
  • Cystosarcoma Phyllodes is an uncommon disease of the breast with variable clinical behaviour.
  • Its incidence is reported as 1% of all breast tumours.
  • In this communication, we present a case of metachronous bilateral benign cystosarcoma phyllodes presenting in a 24year old nulliparous lady.
  • She had right breast mastectomy after two recurrences following local excision.
  • The left breast lesion developed one year after the treatment of the right lesion, again she had to be treated with mastectomy after 2 recurrences.
  • This case unlike most reported cases of bilateral Phyllodes tumour occurred in a nulliparous lady.
  • The problems of diagnosis, clinical behaviour and management are discussed.
  • [MeSH-major] Breast Neoplasms / diagnosis. Phyllodes Tumor / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17668718.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


83. Wu YC, Chen DR, Kuo SJ: Personal experience of ultrasound-guided 14-gauge core biopsy of breast tumor. Eur J Surg Oncol; 2006 Sep;32(7):715-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Personal experience of ultrasound-guided 14-gauge core biopsy of breast tumor.
  • AIM: This study was aimed to examine the efficacy of ultrasound-guided core needle biopsy of breast tumor and compared with the results of previous publications.
  • METHODS: From January 2001 to September 2003, 546 lesions in 513 consecutive patients with the identification of a tumor on ultrasound examination categorized belong and above C3 according to BIRADS (Breast Image Reporting and Data Systems).
  • RESULTS: The patients' ages ranged from 17 to 89 years (mean, 43 years); tumors were from 5.7 to 41.6 mm in diameter (mean, 20.3 mm).
  • There were 341 lesions with benign findings, 202 lesions with malignancy and 3 lesions with atypical ductal hyperplasia (ADH).
  • CONCLUSIONS: Both palpable and impalpable breast lesions should be examined under image guidance and automated core biopsy is the technique of first choice.
  • Fourteen-gauge core biopsy can provide a definitive diagnosis in 99% of solid tumors in this series.
  • [MeSH-major] Biopsy, Fine-Needle. Breast Neoplasms / pathology. Ultrasonography, Interventional
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast / pathology. False Negative Reactions. Female. Humans. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16769196.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


84. Chang RF, Huang SF, Moon WK, Lee YH, Chen DR: Solid breast masses: neural network analysis of vascular features at three-dimensional power Doppler US for benign or malignant classification. Radiology; 2007 Apr;243(1):56-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid breast masses: neural network analysis of vascular features at three-dimensional power Doppler US for benign or malignant classification.
  • PURPOSE: To retrospectively evaluate the accuracy of neural network analysis of tumor vascular features at three-dimensional (3D) power Doppler ultrasonography (US) for classification of breast tumors as benign or malignant, with histologic findings as the reference standard.
  • Three-dimensional power Doppler US images of 221 solid breast masses (110 benign, 111 malignant) were obtained in 221 women (mean age, 46 years; range, 25-71 years).
  • A neural network was used to classify tumors by using these features.
  • RESULTS: Mean values of vessel-to-volume ratio, number of vascular trees, total vessel length, longest path length, number of bifurcations, and vessel diameter were 0.0089 +/- 0.0073 (standard deviation), 26.41 +/- 14.73, 23.02 cm +/- 19.53, 8.44 cm +/- 10.38, 36.31 +/- 37.06, and 0.088 cm +/- 0.021 in malignant tumors, respectively, and 0.0028 +/- 0.0021, 9.69 +/- 6.75, 5.17 cm +/- 4.78, 1.68 cm +/- 1.79, 6.05 +/- 7.55, and 0.064 cm +/- 0.028 in benign tumors, respectively (P < .001 for all six features).
  • CONCLUSION: Three-dimensional power Doppler US images and neural network analysis of features can aid in classification of breast tumors as benign or malignant.
  • [MeSH-major] Breast / blood supply. Breast Neoplasms / ultrasonography. Imaging, Three-Dimensional / methods. Neural Networks (Computer)

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17312276.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Yang JX, Han YJ, Zheng H, Luo RC: [Expression of PAK4 in breast cancer and benign breast pathological changes]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 May;30(5):981-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of PAK4 in breast cancer and benign breast pathological changes].
  • OBJECTIVE: To study the role of p21-activated kinase-4 (PAK4) in the occurrence, progression and metastasis of breast cancer.
  • METHOD: PAK4 expression was detected in 35 cases of normal breast, 22 breast cystic hyperplasia, 28 breast adenofibroma, 37 breast cancer (including 7 non-invasive cancer, 9 early invasive cancer and 21 invasive cancer) and 13 metastatic breast cancer tissues using immunohistochemistry for a comparison of PAK4 expression and distribution.
  • RESULTS: PAK4 was expressed mainly in the cytoplasm of the cancer cells, occasionally in the cell nuclei, and virtually not expressed in the matrix surrounding the breast cells.
  • PAK4 positivity rates increased in the order of normal breast tissues, benign changes (including breast cystic hyperplasea and breast adenoma), breast cancer and metastatic cancer tissues; in the cancer tissues, the positivity rates increased in the order of non-invasive breast tumor, early invasive tumor and invasive tumor tissues.
  • CONCLUSION: PAK4 is closely correlated to the progression and metastasis of breast cancer and may become a new diagnostic and therapeutic target of breast cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. p21-Activated Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501374.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.11 / PAK4 protein, human; EC 2.7.11.1 / p21-Activated Kinases
  •  go-up   go-down


86. Orea-Estudillo D, Jaimes-López L, Bernal-Cano J: [Phyllodes tumor in a pediatric patient. Case report and literature review]. Cir Cir; 2008 Mar-Apr;76(2):165-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumor in a pediatric patient. Case report and literature review].
  • [Transliterated title] Tumor phyllodes en un paciente pediátrico. Informe de un caso y revisión de la literatura.
  • BACKGROUND: Phyllodes tumors occur with a frequency of 0.3- 0.9% and are rare in young women.
  • We present a phyllodes tumor in an 11-year-old female and we reviewed the literature regarding this pathology.
  • CASE REPORT: We present the case of an 11-year-old female with a diagnosis of phyllodes tumor.
  • Histological report demonstrated benign phyllodes tumor.
  • CONCLUSIONS: Small phyllodes tumors can be excised with a 1-cm surgical border, whereas larger phyllodes tumors are treated with simple mastectomy.
  • [MeSH-major] Breast Neoplasms. Phyllodes Tumor

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18492439.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 36
  •  go-up   go-down


87. Bereznaya NM, Kirnasovskaya EA, Vinnichuk YD, Belova OB, Lukyanova NY: Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. Exp Oncol; 2008 Dec;30(4):295-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors.
  • AIM: To study the expression of CD40 by cells of benign and malignant tumors of mammary gland, and to compare the efficacy of lymphocytes antitumor activity against drug resistant and sensitive breast tumors in relevance to CD40 expression.
  • METHODS: Breast tumor explants were cultured with autologous lymphocytes in double diffusion chambers.
  • Expression level of molecules on tumor cells was analyzed using immunohistochemical method (paraffin embedded slides), and on lymphocytes - by the method of indirect immunofluorescence.
  • RESULTS: The highest level of CD40 expression was detected on cells of chemoresistant malignant breast tumors, and the lowest one - on cells of benign breast tumors.
  • The decreased CD40 expression on lymphocytes from patients with drug resistant breast cancer was compared with that on lymphocytes of the patients with drug sensitive breast cancer.
  • The study of antitumor activity of autologous lymphokine activated killer cells (LAK) has shown their pronounced antitumor activity against drug resistant malignant breast tumors.
  • CONCLUSION: Marked antitumor activity of LAK from the patients with drug resistant breast cancer is associated with high expression level of CD40 on tumor cells and with its decreased expression on lymphocytes.
  • [MeSH-major] Antigens, CD40 / biosynthesis. Breast Neoplasms / immunology. Drug Resistance, Neoplasm / immunology. Killer Cells, Lymphokine-Activated / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112427.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antigens, CD40; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


88. Yang W, Zhang S, Chen Y, Li W, Chen Y: Shape symmetry analysis of breast tumors on ultrasound images. Comput Biol Med; 2009 Mar;39(3):231-8
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shape symmetry analysis of breast tumors on ultrasound images.
  • Shape characteristics of malignant and benign breast tumors are significantly different.
  • In this paper, the reflective symmetry of breast tumor shapes on ultrasound images was investigated.
  • A new reflective symmetry measure (RSML) derived from multiscale local area integral invariant was proposed to quantify the shape symmetry of breast tumor, which could be computed directly from the binary mask image without the shape parameterization in terms of arc length.
  • The performance of several symmetry measures for differentiating malignant and benign breast tumors at varying scales was evaluated and compared by receiver operating characteristic (ROC) analysis.
  • RSML with Gaussian kernel at scale 0.04 (related to the maximal diameter) achieved the highest area under the ROC curve (0.85) on the image data of 168 tumors (104 benign and 64 malignant).
  • The experimental results showed that the reflective symmetry of breast tumor shape was capable of providing potential diagnostic information, which could be characterized quantitatively by RSML with the appropriate scale parameter.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Image Interpretation, Computer-Assisted / methods. Ultrasonography / methods. Ultrasonography, Mammary / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178908.001).
  • [ISSN] 1879-0534
  • [Journal-full-title] Computers in biology and medicine
  • [ISO-abbreviation] Comput. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


89. Euhus DM, Bu D, Milchgrub S, Xie XJ, Bian A, Leitch AM, Lewis CM: DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev; 2008 May;17(5):1051-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation in benign breast epithelium in relation to age and breast cancer risk.
  • BACKGROUND: Many established breast cancer risk factors are related to the timing and duration of exposure to reproductive hormones, which are known to drive breast epithelial cell proliferation.
  • The epigenetic molecular clock hypothesis suggests that CpG island methylation records the cell division history of benign epithelium.
  • In proliferative epithelium, such as breast, this may provide an individualized cell-based measure of cancer risk.
  • METHODS: Methylation of cyclin D2, APC, HIN1, RASSF1A, and RAR-beta2 was measured by quantitative multiplex methylation-specific PCR in 290 benign and malignant breast epithelial cell samples obtained by palpation-directed fine-needle aspiration biopsy from 164 women.
  • Univariate, multivariate, and unsupervised cluster analysis was used to establish the relationship between TSG methylation and a personal history of breast cancer, predicted breast cancer risk, and specific breast cancer risk factors.
  • RESULTS: RASSF1A methylation was highly correlated with breast cancer risk [odds ratio (OR), 5.28; 95% confidence interval (95% CI), 1.95-14.32; P = 0.001], atypical cytology (OR, 4.11; 95% CI, 1.30-12.98; P = 0.016), and benign breast disease requiring biopsy (OR, 6.12; 95% CI, 1.41-26.51; P = 0.016).
  • CONCLUSIONS: TSG methylation increases in benign breast epithelium with increasing age.
  • Because it is independently related to a personal history of benign or malignant breast disease and to predicted breast cancer risk, it may have value for breast cancer risk stratification and as a surrogate endpoint marker in prevention trials.
  • [MeSH-major] Breast Neoplasms / genetics. DNA Methylation
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Breast / pathology. Cluster Analysis. CpG Islands / genetics. Cyclin D2. Cyclins / genetics. Cytokines / genetics. Epithelium / pathology. Female. Genes, APC. Humans. Middle Aged. Multivariate Analysis. Polymerase Chain Reaction. Receptors, Retinoic Acid / genetics. Risk Factors. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483325.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / Cytokines; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / SCGB3A1 protein, human; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta
  •  go-up   go-down


90. Vasaturo F, Sallusti E, Gradilone A, Malacrino C, Nardo T, Avagnano G, Aglianò AM, Granato T, De Vincenzi B, Coppotelli G, Marzullo A, Soda G, Simonelli L, Modesti M, Scarpa S: Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast. Int J Oncol; 2005 Oct;27(4):1005-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast.
  • The expression of the extracellular matrix-related genes, such as fibronectin, laminin and tenascin C, and apoptosis-related genes, such as bax, bcl2 and survivin, was evaluated by reverse transcription-polymerase chain reaction (RT-PCR) and by immunohistochemistry in normal breast tissue and benign and malignant breast tumors and then correlated to several clinical parameters: estrogen and progesterone receptors, Ki67, ErbB2, tumor size, lymph node status and grading.
  • Seventy-three breast tissue samples were examined.
  • In addition, we found a statistically significant increase in survivin transcription in malign tumors compared to fibroadenomas (P=0.024).
  • The negative correlation between laminin transcription and Ki67 could suggest that laminin impacts negatively on tumor proliferation, and the positive correlation between fibronectin and lymph node status may lead to consider fibronectin as predictive of long distance metastasis.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor. Breast Diseases / metabolism. Breast Neoplasms / metabolism. Carcinoma / metabolism. Extracellular Matrix / metabolism. Gene Expression Regulation. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Cell Differentiation. Cell Line, Tumor. Cell Proliferation. Cytoplasm / metabolism. Female. Fibronectins / metabolism. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Ki-67 Antigen / biosynthesis. Laminin / metabolism. Lymphatic Metastasis. Microtubule-Associated Proteins / metabolism. Neoplasm Metastasis. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. RNA / metabolism. Receptor, ErbB-2 / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tenascin / metabolism. bcl-2-Associated X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142317.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / Inhibitor of Apoptosis Proteins; 0 / Ki-67 Antigen; 0 / Laminin; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tenascin; 0 / bcl-2-Associated X Protein; 63231-63-0 / RNA; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


91. Preda A, Novikov V, Möglich M, Floyd E, Turetschek K, Shames DM, Roberts TP, Corot C, Carter WO, Brasch RC: Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation. Eur Radiol; 2005 Nov;15(11):2268-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation.
  • Carboxymethyldextran (CMD)-A2-Gd-DOTA, a slow clearance blood pool contrast agent with a molecular weight of 52.1 kDa, designed to have intravascular residence for more than 1 h, was evaluated for its potential to characterize and differentiate the microvessels of malignant and benign breast tumors.
  • Precontrast single-slice inversion-recovery snapshot FLASH and dynamic contrast-enhanced MRI using an axial T1-weighted three-dimensional spoiled gradient recalled sequence was performed in 30 Sprague-Dawley rats with chemically induced breast tumors.
  • Endothelial transfer coefficient and fractional plasma volume of the breast tumors were estimated from MRI data acquired with CMD-A2-Gd-DOTA enhancement injected at a dose of 0.1 mmol Gd/kg body weight using a two-compartment bidirectional model of the tumor tissue.
  • The correlation between MRI microvessel characteristics and histopathological tumor grade was determined using the Scarff-Bloom-Richardson method.
  • Using CMD-A2-Gd-DOTA, no significant correlations were found between the MR-estimated endothelial transfer coefficient or plasma volumes with histological tumor grade.
  • Analysis of CMD-A2-Gd-DOTA-enhanced MR kinetic data failed to demonstrate feasibility for the differentiation of benign from malignant tumors or for image-based tumor grading.
  • [MeSH-major] Magnetic Resonance Imaging. Mammary Neoplasms, Experimental / blood supply. Mammary Neoplasms, Experimental / pathology. Organometallic Compounds

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16012822.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA82923
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / carboxymethyl-dextran-A2-gadolinium-DOTA
  •  go-up   go-down


92. Alvarenga AV, Pereira WC, Infantosi AF, Azevedo CM: Complexity curve and grey level co-occurrence matrix in the texture evaluation of breast tumor on ultrasound images. Med Phys; 2007 Feb;34(2):379-87
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complexity curve and grey level co-occurrence matrix in the texture evaluation of breast tumor on ultrasound images.
  • This work aims at investigating texture parameters in distinguishing malign and benign breast tumors on ultrasound images.
  • A rectangular region of interest (ROI) containing the tumor and its neighboring was defined for each image.
  • The same was carried out for internal tumor region, hence, totaling 20 parameters.
  • The most relevant individual parameters were the contrast (con) (from the GLCM over the ROI) and the maximum value (mvi) from the CC just for the tumor internal region).
  • When they were taken together, a correct classification slightly over 80% of the breast tumors was achieved.
  • These findings suggest that the texture parameters can be useful to help radiologist in distinguishing between benign or malign breast tumors on ultrasound images.
  • [MeSH-major] Algorithms. Artificial Intelligence. Breast Neoplasms / diagnostic imaging. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Pattern Recognition, Automated / methods. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388154.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Ma X, Kundu N, Ioffe OB, Goloubeva O, Konger R, Baquet C, Gimotty P, Reader J, Fulton AM: Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities. Mol Cancer Res; 2010 Oct;8(10):1310-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities.
  • Cyclooxygenase-2 is frequently overexpressed and associated with poor prognosis in breast cancer.
  • EP4, expressed on malignant breast cells, promotes metastasis; however, a role for EP1 in metastasis has not been investigated.
  • Using a murine model of metastatic breast cancer, we now show that pharmacologic antagonism of EP1 with SC19220 or AH6809 promoted lung colonization of mammary tumor cells by 3.7- to 5.4-fold.
  • Likewise, reducing EP1 gene expression by shRNA also increased metastatic capacity relative to cells transfected with nonsilencing vector but did not affect the size of transplanted tumors.
  • Examination of invasive ductal carcinomas by immunohistochemistry shows that EP1 was detected in both the cytoplasm and nucleus of benign ducts as well as malignant cells in some samples, but was absent or limited to either the nucleus or cytoplasm in other malignant samples.
  • Overall survival for women with tumors that were negative for nuclear EP1 was significantly worse than for women with EP1 expression (P = 0.008).
  • Comparing EP1 mRNA in breast tumors from African American and European American women revealed that many more African American breast tumors lacked detectable EP1 mRNA (P = 0.04).
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / prevention & control. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Receptors, Prostaglandin E, EP1 Subtype / physiology. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Animals. Biomarkers, Tumor / antagonists & inhibitors. Biomarkers, Tumor / biosynthesis. Cell Line, Tumor. Disease Models, Animal. Female. Humans. Mice. Mice, Inbred BALB C. Nuclear Proteins / antagonists & inhibitors. Nuclear Proteins / biosynthesis. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5093-6 [10537280.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Carcinogenesis. 2001 Dec;22(12):2001-4 [11751431.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):28-32 [11782353.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):632-5 [11830510.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2810-6 [12788892.001]
  • [Cites] Cancer Sci. 2003 Jul;94(7):618-21 [12841871.001]
  • [Cites] Trends Pharmacol Sci. 2003 Jul;24(7):335-40 [12871665.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35451-7 [12824187.001]
  • [Cites] Exp Cell Res. 2003 Oct 1;289(2):265-74 [14499627.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):591-6 [14688410.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1584-8 [14996713.001]
  • [Cites] Invasion Metastasis. 1983;3(1):22-31 [6677618.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2047-50 [1849040.001]
  • [Cites] J Cell Physiol. 1996 Nov;169(2):401-9 [8908208.001]
  • [Cites] Am J Obstet Gynecol. 1997 Jun;176(6):S233-9 [9215214.001]
  • [Cites] Br J Pharmacol. 1997 Sep;122(2):217-24 [9313928.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15792-7 [9861049.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1193-226 [10508233.001]
  • [Cites] J Invest Dermatol. 2005 Oct;125(4):818-25 [16185283.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9304-11 [16230392.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):205-11 [16417238.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2923-7 [16540639.001]
  • [Cites] CA Cancer J Clin. 2006 May-Jun;56(3):168-83 [16737949.001]
  • [Cites] Can J Physiol Pharmacol. 2006 Mar-Apr;84(3-4):287-97 [16902576.001]
  • [Cites] Can J Physiol Pharmacol. 2006 Mar-Apr;84(3-4):377-91 [16902584.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24831-46 [16790433.001]
  • [Cites] Trends Pharmacol Sci. 2006 Sep;27(9):458-60 [16870271.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9665-72 [17018624.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9794-7 [17047037.001]
  • [Cites] Mod Pathol. 2008 Jan;21(1):15-21 [17906615.001]
  • [Cites] J Biol Chem. 2008 Feb 8;283(6):3433-44 [18083712.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7750-9 [18829529.001]
  • [Cites] J Exp Ther Oncol. 2008;7(4):299-312 [19227010.001]
  • [Cites] Mol Cancer Ther. 2009 Mar;8(3):490-8 [19276169.001]
  • [Cites] Breast Cancer Res Treat. 2009 Sep;117(2):235-42 [18792778.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2009 Oct;81(4):279-90 [19625175.001]
  • (PMID = 20858737.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Grant] United States / BLRD VA / BX / I01 BX000169; United States / NCI NIH HHS / CA / P30 CA134274; United States / NCI NIH HHS / CA / R01 CA120278
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Receptors, Prostaglandin E, EP1 Subtype; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ NIHMS230113; NLM/ PMC2974016
  •  go-up   go-down


94. Corben AD, Nehhozina T, Garg K, Vallejo CE, Brogi E: Endosalpingiosis in axillary lymph nodes: a possible pitfall in the staging of patients with breast carcinoma. Am J Surg Pathol; 2010 Aug;34(8):1211-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endosalpingiosis in axillary lymph nodes: a possible pitfall in the staging of patients with breast carcinoma.
  • The occurrence of benign epithelial inclusions in lymph nodes is well documented and can sometimes mimic metastatic carcinoma.
  • Benign müllerian inclusions, such as endometriosis and endosalpingiosis, are common in pelvic and para-aortic lymph nodes, but their presence in supradiaphragmatic lymph nodes is a rare event.
  • We report our experience with 3 patients found to have endosalpingiosis in axillary sentinel lymph nodes obtained for staging of breast carcinoma.
  • Endosalpingiosis had been misinterpreted as metastatic carcinoma at another hospital in 1 of the 3 patients, with subsequent dissection of 19 additional benign axillary lymph nodes.
  • Morphologic identification of ciliated cells and "peg" cells is most helpful to recognize this benign inclusion, and positive immunoreactivity for WT1 and/or PAX8 can be used to support the diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Diagnostic Errors / prevention & control. Epithelial Cells / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cilia. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Staging. Paired Box Transcription Factors / analysis. Predictive Value of Tests. Sentinel Lymph Node Biopsy. Unnecessary Procedures. WT1 Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20631604.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / WT1 Proteins
  • [Number-of-references] 32
  •  go-up   go-down


95. Roncella S, Ferro P, Franceschini MC, Bacigalupo B, Dessanti P, Sivori M, Carletti AM, Fontana V, Canessa PA, Pistillo MP, Fedeli F: Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin. Diagn Mol Pathol; 2010 Jun;19(2):92-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin.
  • As was reported that human mammaglobin (hMAM) may be expressed in malignant pleural effusions (PEs), we investigated the relevance of hMAM reverse-transcriptase polymerase chain reaction (RT-PCR) for their diagnosis and determination of primary origin.
  • Two hundred and twenty-eight malignant (132 male, 96 female) and 185 benign (132 male, 53 female) PEs were investigated.
  • Statistical analyses evaluated the diagnostic performance parameters in all PEs and in cytologically negative malignant PEs, the association between hMAM and benign or malignant status by the direct index of correlation [diagnostic odds ratio (DOR)], chi test, and P value (P).
  • In addition, the discriminative diagnostic power of hMAM expression, independently in breast cancer, lung cancer (LC), malignant mesothelioma (MM), and other cancers was evaluated.
  • In the entire patient population, hMAM was detected in 45.6% and 5.4% of malignant and benign PEs, respectively, in the male group in 41.7% and 4.5% and in the female group in 51.0% and 7.5% of malignant and benign PEs, respectively.
  • A statistically significant correlation between hMAM and malignancy was found in the entire population (DOR=14.68, P<0.001) and in the male (DOR=15.00, P<0.001) or female (DOR=12.77, P<0.001) groups. hMAM RT-PCR increased the diagnostic rate of malignant PEs as it allowed us to detect as malignant 32.1% of cytologically negative PEs.
  • In female patients the positivity of hMAM indicated with higher probability (50.8%) the origin of PEs from breast cancer but lower probability from LC (17%), MM (9.4%), or other cancers (15.1%), whereas in male patients it indicated with similar probability (about 40%) the origin from LC or MM.
  • Our results suggest that hMAM RT-PCR may provide information both in the diagnosis of PE and in the search for the primary site of neoplasia, either in male or female patients.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / diagnosis. Neoplasm Proteins / genetics. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / etiology. Reverse Transcriptase Polymerase Chain Reaction / methods. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Male. Mammaglobin A. Middle Aged. United States. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20502186.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


96. Pérez M, Liu Y, Schootman M, Aft RL, Schechtman KB, Gillanders WE, Jeffe DB: Changes in sexual problems over time in women with and without early-stage breast cancer. Menopause; 2010 Sep-Oct;17(5):924-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in sexual problems over time in women with and without early-stage breast cancer.
  • OBJECTIVE: We aimed to evaluate whether age-matched women with and without early-stage breast cancer differentially experience sexual problems over time and whether changes in patients' problems differ by type of surgical procedure.
  • METHODS: We conducted four interviews (4-6 wk, 6 mo, and 1 and 2 y) after tumor resection (patients) or after a negative/benign screening mammogram (controls).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Sexual Problems in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast. 2008 Oct;17(5):436-40 [18479922.001]
  • [Cites] J Clin Epidemiol. 2009 Jul;62(7):759-65 [19013762.001]
  • [Cites] J Stud Alcohol Drugs. 2009 Jul;70(4):623-7 [19515304.001]
  • [Cites] J Environ Manage. 2009 Aug;90(11):3528-33 [19647362.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2371-80 [10561299.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2659-69 [10561339.001]
  • [Cites] Psychooncology. 1999 Nov-Dec;8(6):538-45 [10607986.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):946-54 [10679665.001]
  • [Cites] Arch Intern Med. 2000 Apr 10;160(7):953-8 [10761960.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 5;92(13):1054-64 [10880548.001]
  • [Cites] J Consult Clin Psychol. 2000 Aug;68(4):697-709 [10965644.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 6;92(17):1422-9 [10974078.001]
  • [Cites] Addiction. 2000 Nov;95 Suppl 3:S381-94 [11132364.001]
  • [Cites] Menopause. 2001 Summer;8(2):111-9 [11256871.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1885-92 [11283119.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1288-98 [11571745.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;949:143-50 [11795346.001]
  • [Cites] Br J Cancer. 2002 May 20;86(10):1546-50 [12085202.001]
  • [Cites] Behav Res Methods Instrum Comput. 2002 May;34(2):151-7 [12109005.001]
  • [Cites] Breast Cancer Res Treat. 2002 Oct;75(3):241-8 [12353813.001]
  • [Cites] CA Cancer J Clin. 2002 Sep-Oct;52(5):256-76 [12363325.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2254-62 [11304779.001]
  • [Cites] Psychooncology. 2002 Nov-Dec;11(6):505-17 [12476432.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3659-64 [14512398.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6):799-813 [14663780.001]
  • [Cites] Am J Epidemiol. 2004 Feb 15;159(4):364-72 [14769640.001]
  • [Cites] Breast J. 2004 May-Jun;10(3):223-31 [15125749.001]
  • [Cites] Psychooncology. 2004 May;13(5):295-308 [15133771.001]
  • [Cites] Health Qual Life Outcomes. 2004 May 18;2:25 [15149547.001]
  • [Cites] Nurs Res. 1982 Sep-Oct;31(5):278-83 [6922469.001]
  • [Cites] Am J Psychiatry. 1983 Jun;140(6):734-9 [6846631.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1231-7 [3044575.001]
  • [Cites] J Consult Clin Psychol. 1988 Dec;56(6):893-7 [3204199.001]
  • [Cites] CA Cancer J Clin. 1991 Mar-Apr;41(2):112-20 [1900030.001]
  • [Cites] Cancer. 1992 Apr 1;69(7):1729-38 [1551058.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1292-8 [1634919.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):783-93 [8478672.001]
  • [Cites] Annu Rev Public Health. 1993;14:43-68 [8323597.001]
  • [Cites] J Natl Cancer Inst Monogr. 1994;(16):177-82 [7999462.001]
  • [Cites] Cancer. 1995 Jan 1;75(1):54-64 [7804978.001]
  • [Cites] Arch Sex Behav. 1994 Dec;23(6):627-43 [7872859.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 20;87(18):1372-82 [7658498.001]
  • [Cites] Med Care. 1996 Jan;34(1):73-84 [8551813.001]
  • [Cites] Breast Cancer Res Treat. 1996;38(2):183-99 [8861837.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):974-86 [9060536.001]
  • [Cites] CA Cancer J Clin. 1997 May-Jun;47(3):150-3 [9152172.001]
  • [Cites] Health Psychol. 1997 May;16(3):284-98 [9152708.001]
  • [Cites] Ann Surg Oncol. 1997 Oct-Nov;4(7):564-9 [9367022.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):487-94 [9469332.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):501-14 [9469334.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(3):307-14 [9640214.001]
  • [Cites] Psychooncology. 1998 Nov-Dec;7(6):470-82 [9885088.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):359-66 [10379856.001]
  • [Cites] J Sex Marital Ther. 1999 Jul-Sep;25(3):237-50 [10407796.001]
  • [Cites] Breast Cancer Res Treat. 1999 Mar;54(2):109-15 [10424401.001]
  • [Cites] Breast Cancer Res Treat. 1999 May;55(2):189-99 [10481946.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5526-33 [16110013.001]
  • [Cites] Breast J. 2005 Nov-Dec;11(6):440-7 [16297089.001]
  • [Cites] J Sex Med. 2005 Jul;2(4):469-77 [16422841.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2815-21 [16782919.001]
  • [Cites] Psychooncology. 2006 Jul;15(7):579-94 [16287197.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4875-81 [17050872.001]
  • [Cites] Br J Cancer. 2006 Dec 18;95(12):1626-31 [17160080.001]
  • [Cites] Eur J Cancer. 2007 Feb;43(3):549-56 [17140788.001]
  • [Cites] J Psychosoc Oncol. 2007;25(2):19-36 [17613483.001]
  • [Cites] N Engl J Med. 2007 Aug 23;357(8):762-74 [17715410.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3078-89 [17574501.001]
  • [CommentIn] Menopause. 2010 Sep-Oct;17(5):894-5 [20700064.001]
  • (PMID = 20461020.001).
  • [ISSN] 1530-0374
  • [Journal-full-title] Menopause (New York, N.Y.)
  • [ISO-abbreviation] Menopause
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA91842; United States / NCI NIH HHS / CA / R01 CA102777; United States / NCI NIH HHS / CA / R01 CA102777-05; United States / NCI NIH HHS / CA / CA102777-05; United States / NCI NIH HHS / CA / P30 CA091842; United States / NCI NIH HHS / CA / R01CA102777
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS221562; NLM/ PMC2939280
  •  go-up   go-down


97. Rageth CJ, Tausch C: Intramammarian flap reconstruction (IFR) technique in breast conserving surgery. Breast; 2009 Dec;18(6):387-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramammarian flap reconstruction (IFR) technique in breast conserving surgery.
  • As large segmentectomies often lead to asymmetries and indentations in the breast, numerous oncoplastic reconstruction methods have been published over the past years.
  • First, the breast gland body is being detached from the pectoralis major muscle; then the largest part of the remaining gland body is being cut horizontally parallel to the thoracic wall, exactly in the middle between the skin and the pectoralis major muscle.
  • The pectoral part of the gland body can then be placed into the tumor bed without tension as a f;ap with a length of approximately 7-14 cm and a width of approximately 4-10 cm.
  • In 2007, the first author performed a total of 134 breast conserving surgeries (9 benign and 125 malignant diagnoses) which have been prospectively documented.
  • The results in the 4 remaining patients were cosmetically unsatisfactory; 3 were treated with and 1 without the intramammarian flap reconstruction.In most cases the technique leads to a quick and acceptable filling of the defect and avoids nipple deviation even after a large segmentectomy, so that the breast shape can be preserved and the original breast size is being only marginally reduced.
  • [MeSH-major] Breast / surgery. Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / surgery. Mastectomy, Segmental / methods. Surgical Flaps
  • [MeSH-minor] Aged. Aged, 80 and over. Breast Diseases / surgery. Female. Humans. Hyperplasia. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19913416.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


98. Deryugina EI, Quigley JP: Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta; 2010 Jan;1803(1):103-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions.
  • A number of extensive reviews are available discussing the roles of MMPs in various aspects of cancer progression from benign tumor formation to overt cancer present with deadly metastases.
  • This review will focus specifically on the evidence functionally linking the MMPs and tumor-induced angiogenesis in various in vivo models.
  • Emphasis has been placed on the cellular origin of the MMPs in tumor tissue, the requirement of proMMP activation and the resulting proteolytic activity for the induction and progression of tumor angiogenesis, and the pleiotropic roles for some of the MMPs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7968-75 [16912171.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12493-8 [16891410.001]
  • [Cites] Cell Cycle. 2006 Aug;5(15):1597-601 [16880743.001]
  • [Cites] J Cell Biol. 2006 Oct 9;175(1):179-91 [17030988.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):558-64 [15363807.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6965-72 [15466188.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):409-21 [15488763.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 Sep-Oct;1(6):475-9 [1302560.001]
  • [Cites] J Cell Biol. 1993 Sep;122(6):1351-9 [8376467.001]
  • [Cites] Hybridoma. 1993 Aug;12(4):349-63 [8244415.001]
  • [Cites] Nature. 1994 Jul 7;370(6484):61-5 [8015608.001]
  • [Cites] Microvasc Res. 1994 Jan;47(1):31-40 [7517489.001]
  • [Cites] Cell. 1994 Oct 21;79(2):315-28 [7525077.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Cell. 1996 May 31;85(5):683-93 [8646777.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):30174-80 [8939968.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):26-45 [9034785.001]
  • [Cites] Cell. 1997 Mar 21;88(6):801-10 [9118223.001]
  • [Cites] J Clin Invest. 1997 Apr 1;99(7):1534-45 [9119997.001]
  • [Cites] Lab Invest. 1997 Oct;77(4):345-55 [9354769.001]
  • [Cites] Cell. 1998 Feb 6;92(3):391-400 [9476898.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1048-51 [9500469.001]
  • [Cites] Cell. 1998 May 1;93(3):411-22 [9590175.001]
  • [Cites] Eur J Immunol. 1998 Jun;28(6):1773-84 [9645358.001]
  • [Cites] Am J Pathol. 1998 Sep;153(3):757-65 [9736026.001]
  • [Cites] Am J Pathol. 2008 Dec;173(6):1736-46 [18988801.001]
  • [Cites] Histochem Cell Biol. 2008 Dec;130(6):1119-30 [19005674.001]
  • [Cites] Nature. 2008 Dec 11;456(7223):809-13 [18997771.001]
  • [Cites] Nature. 2008 Dec 11;456(7223):814-8 [18997773.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):21-34 [19111878.001]
  • [Cites] Matrix Biol. 2009 Jan;28(1):3-10 [19010413.001]
  • [Cites] J Cell Biol. 2009 Feb 9;184(3):399-408 [19188491.001]
  • [Cites] Dev Cell. 2009 Feb;16(2):222-31 [19217424.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1517-26 [19208838.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):232-9 [19249681.001]
  • [Cites] Cell. 2009 Mar 6;136(5):839-51 [19217150.001]
  • [Cites] Clin Exp Metastasis. 2009;26(4):381-97 [18958576.001]
  • [Cites] J Cell Biol. 2009 Apr 6;185(1):11-9 [19332889.001]
  • [Cites] Int J Exp Pathol. 2009 Jun;90(3):222-31 [19563607.001]
  • [Cites] J Biol Chem. 2009 Sep 18;284(38):25854-66 [19608737.001]
  • [Cites] Curr Opin Cell Biol. 2009 Oct;21(5):645-53 [19616423.001]
  • [Cites] J Leukoc Biol. 2009 Nov;86(5):1065-73 [19741157.001]
  • [Cites] FASEB J. 2005 Feb;19(2):234-6 [15550552.001]
  • [Cites] Breast Dis. 2004;20:145-53 [15687715.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):211-7 [15766659.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):265-72 [15781313.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3200-8 [15833851.001]
  • [Cites] Genes Dev. 2005 Apr 15;19(8):979-91 [15805464.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78 [15863032.001]
  • [Cites] Circ Res. 2005 May 13;96(9):930-8 [15890980.001]
  • [Cites] J Cell Sci. 2005 May 15;118(Pt 10):2143-53 [15855236.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3967-79 [15899784.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):849-60 [15729716.001]
  • [Cites] J Cell Biol. 2005 May 23;169(4):681-91 [15911882.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):21882-92 [15824107.001]
  • [Cites] Exp Cell Res. 2005 Jul 15;307(2):292-304 [15950618.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):292-8 [15979458.001]
  • [Cites] Cell. 2005 Jul 1;121(7):1109-21 [15989959.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):2890-9 [16116175.001]
  • [Cites] J Exp Med. 2005 Sep 5;202(5):663-71 [16147977.001]
  • [Cites] Anticancer Drugs. 2005 Oct;16(9):997-1002 [16162976.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):211-26 [16169466.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1399-408 [16170032.001]
  • [Cites] J Exp Med. 2005 Sep 19;202(6):739-50 [16157686.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):299-309 [16226705.001]
  • [Cites] J Cell Biochem. 2005 Dec 1;96(5):897-905 [16149080.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):1-8 [15920734.001]
  • [Cites] Circ Res. 2005 Nov 25;97(11):1093-107 [16306453.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1429-37 [12368215.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] J Cell Mol Med. 2002 Jul-Sep;6(3):439-46 [12417062.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):561-73 [12492497.001]
  • [Cites] J Cell Biol. 2003 Jan 20;160(2):267-77 [12527751.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2002 Dec;37(6):375-536 [12540195.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] Vet Pathol. 2003 May;40(3):227-36 [12724562.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2454-61 [12750266.001]
  • [Cites] Nat Med. 2003 Jun;9(6):702-12 [12778169.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):153-66 [12784994.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;996:49-60 [12799282.001]
  • [Cites] Trends Cell Biol. 2003 Jul;13(7):366-75 [12837607.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):589-601 [12842087.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):932-6 [16355210.001]
  • [Cites] Blood. 2006 Jan 1;107(1):317-27 [16174763.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):259-66 [16397239.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2006;46:301-15 [16402907.001]
  • [Cites] Cell. 2006 Jan 13;124(1):175-89 [16413490.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):310-8 [16406506.001]
  • [Cites] Nat Methods. 2006 Apr;3(4):259-61 [16554829.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):728-34 [16524717.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):9-34 [16680569.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):35-43 [16680570.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):77-86 [16680574.001]
  • [Cites] Cell Cycle. 2006 Apr;5(8):812-7 [16627996.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5234-41 [16707448.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6149-55 [16778188.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7766-74 [16885380.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):159-66 [16857321.001]
  • [Cites] FASEB J. 2007 Aug;21(10):2580-91 [17392479.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):893-904 [17618273.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):800-8 [17851543.001]
  • [Cites] Bioessays. 2007 Nov;29(11):1159-68 [17935210.001]
  • [Cites] Mol Biol Cell. 2007 Nov;18(11):4222-31 [17699594.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):717-24 [17717634.001]
  • [Cites] Mol Cell Biol. 2007 Dec;27(24):8454-65 [17908800.001]
  • [Cites] Matrix Biol. 2007 Oct;26(8):587-96 [17669641.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20262-7 [18077379.001]
  • [Cites] Science. 2008 Jan 11;319(5860):163-4 [18187643.001]
  • [Cites] Science. 2008 Jan 11;319(5860):195-8 [18187653.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):181-3 [18328420.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):193-205 [18328424.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):206-20 [18328425.001]
  • [Cites] Curr Opin Hematol. 2008 May;15(3):197-203 [18391785.001]
  • [Cites] Neoplasia. 2008 Apr;10(4):329-40 [18392134.001]
  • [Cites] Cardiovasc Res. 2008 May 1;78(2):203-12 [18079100.001]
  • [Cites] Annu Rev Biochem. 2008;77:383-414 [18366325.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17740-8 [18441011.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):144-53 [18556780.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):579-91 [18596824.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):592-603 [18650835.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6251-9 [18676849.001]
  • [Cites] Cell. 2008 Aug 22;134(4):679-91 [18724940.001]
  • [Cites] J Biol Chem. 2008 Nov 7;283(45):30433-7 [18650443.001]
  • [Cites] Methods Enzymol. 2008;444:21-41 [19007659.001]
  • [Cites] Methods Enzymol. 2008;444:255-69 [19007668.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2108-14 [18772495.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4340-51 [14530359.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3262-9 [12855577.001]
  • [Cites] Nat Genet. 2003 Nov;35(3):252-7 [14517555.001]
  • [Cites] Cell Tissue Res. 2003 Oct;314(1):15-23 [12883993.001]
  • [Cites] Brain. 2003 Dec;126(Pt 12):2738-49 [14506071.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5370-5 [14638740.001]
  • [Cites] Blood. 2004 Jan 1;103(1):110-9 [12958067.001]
  • [Cites] Leuk Res. 2004 Mar;28(3):221-2 [14687614.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] Circ Res. 2004 Feb 6;94(2):262-8 [14670843.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1675-86 [14996727.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1687-94 [14996728.001]
  • [Cites] Semin Thromb Hemost. 2004 Feb;30(1):109-17 [15034802.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13564-74 [14729679.001]
  • [Cites] J Cell Sci. 2004 Apr 1;117(Pt 9):1847-57 [15075244.001]
  • [Cites] J Cell Physiol. 2004 Jul;200(1):11-9 [15137053.001]
  • [Cites] J Histochem Cytochem. 2004 Jun;52(6):711-22 [15150280.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5304-13 [15169894.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):163-76 [10652271.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):361-81 [10666364.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2202-7 [10681423.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1641-6 [9811357.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6845-52 [9862716.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):35-48 [9887098.001]
  • [Cites] APMIS. 1999 Jan;107(1):38-44 [10190278.001]
  • [Cites] Blood. 1999 May 1;93(9):3064-73 [10216103.001]
  • [Cites] J Biol Chem. 1999 May 7;274(19):13066-76 [10224058.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Exp Cell Res. 1999 Jul 10;250(1):122-30 [10388526.001]
  • [Cites] EMBO J. 1999 Jul 15;18(14):3964-72 [10406801.001]
  • [Cites] Cell. 1999 Jul 23;98(2):137-46 [10428026.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):757-67 [15545316.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):769-81 [15557125.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1292-8 [15516694.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27633-45 [15066996.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):617-29 [15286728.001]
  • [Cites] J Clin Invest. 2004 Sep;114(5):623-33 [15343380.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1102-13 [10713697.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):15-23 [10728589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3884-9 [10760260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4052-7 [10737763.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1647-54 [10815882.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):26411-5 [10827175.001]
  • [Cites] Exp Cell Res. 2000 Oct 10;260(1):73-84 [11010812.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12227-32 [11035804.001]
  • [Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]
  • [Cites] FEBS Lett. 2000 Dec 15;486(3):247-51 [11119712.001]
  • [Cites] Hybridoma. 2000 Oct;19(5):375-85 [11128027.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(1-2):109-20 [11191049.001]
  • [Cites] Biochim Biophys Acta. 2000 Dec 11;1499(1-2):19-33 [11118636.001]
  • [Cites] Methods Mol Biol. 2001;151:411-5 [11217316.001]
  • [Cites] Exp Cell Res. 2001 Feb 15;263(2):209-23 [11161720.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Mar;42(3):853-9 [11222550.001]
  • [Cites] J Exp Med. 2001 Mar 19;193(6):727-40 [11257139.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2323-32 [11290594.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 30;282(2):463-73 [11401482.001]
  • [Cites] J Leukoc Biol. 2001 Jun;69(6):851-9 [11404367.001]
  • [Cites] J Clin Invest. 2001 Aug;108(3):349-55 [11489925.001]
  • [Cites] J Cell Biol. 2001 Sep 3;154(5):1069-79 [11535623.001]
  • [Cites] Cancer Lett. 2001 Nov 28;173(2):175-82 [11597792.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12485-90 [11606713.001]
  • [Cites] Radiology. 2001 Nov;221(2):523-9 [11687699.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Cell. 2001 Dec 14;107(6):789-800 [11747814.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):272-81 [11803470.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):580-8 [11809713.001]
  • [Cites] Acta Haematol. 2001;106(4):162-9 [11815713.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):7377-85 [11741954.001]
  • [Cites] FASEB J. 2002 Mar;16(3):379-89 [11874987.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):9749-56 [11724803.001]
  • [Cites] FASEB J. 2002 Apr;16(6):555-64 [11919158.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] J Hematother Stem Cell Res. 2002 Apr;11(2):207-14 [11983094.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Cell. 2002 May 31;109(5):625-37 [12062105.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42 [12165638.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36288-95 [12114504.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5580-9 [12359771.001]
  • [Cites] Cell. 2003 Jul 11;114(1):33-45 [12859896.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5060-4 [12941835.001]
  • [Cites] Eur J Biochem. 2003 Sep;270(18):3739-49 [12950257.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5224-9 [14500349.001]
  • [Cites] J Leukoc Biol. 2006 Dec;80(6):1183-96 [16997855.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11089-93 [17145848.001]
  • [Cites] Clin Exp Metastasis. 2006;23(7-8):335-44 [17136575.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33 [17318226.001]
  • [Cites] Biochim Biophys Acta. 2007 Mar;1773(3):400-7 [17187878.001]
  • [Cites] J Biol Chem. 2007 Mar 2;282(9):6899-905 [17204469.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2649-56 [17363585.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3310-9 [17409440.001]
  • [Cites] Mol Cell Proteomics. 2007 Apr;6(4):611-23 [17200105.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):765-70 [17429393.001]
  • [Cites] J Cell Sci. 2007 May 1;120(Pt 9):1607-14 [17405818.001]
  • [Cites] Lancet Oncol. 2007 May;8(5):444-8 [17466902.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4353-63 [17483349.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):3068-78 [17505010.001]
  • (PMID = 19800930.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA105412; United States / NCI NIH HHS / CA / R01 CA055852-16; United States / NCI NIH HHS / CA / CA055852-16; United States / NCI NIH HHS / CA / R01 CA055852; United States / NCI NIH HHS / CA / R01 CA129484
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 240
  • [Other-IDs] NLM/ NIHMS154042; NLM/ PMC2824055
  •  go-up   go-down


99. Enfield LC, Gibson AP, Hebden JC, Douek M: Optical tomography of breast cancer-monitoring response to primary medical therapy. Target Oncol; 2009 Sep;4(3):219-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical tomography of breast cancer-monitoring response to primary medical therapy.
  • Studies have demonstrated that diffuse optical imaging and spectroscopy are able to distinguish malignant lesions from benign tissues.
  • Breast cancer is characterized by an increase in total hemoglobin and a decrease in tissue oxygen saturation.
  • Benign lesions such as cysts and fibroadenomas have also been studied, with less conclusive results.
  • This provides a unique functional and dynamic imaging method that reflects changes in tumor angiogenesis and hypoxia.
  • When breast cancers are treated with primary medical therapy, this can result in a selective antiangiogenic effect that could help predict response to treatment earlier than by assessment of tumor size.
  • Diffuse optical imaging and spectroscopy have been used to scan women at several points prior to and during their neoadjuvant chemotherapy treatment, with images and data showing physiological changes in the tumor in response to treatment.
  • In the women who respond to therapy, the total hemoglobin concentration decreases and the level of oxygenation increases in the tumor over the course of the treatment.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / therapy. Tomography, Optical / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19777322.001).
  • [ISSN] 1776-260X
  • [Journal-full-title] Targeted oncology
  • [ISO-abbreviation] Target Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 99
  •  go-up   go-down


100. Schulz M, Lamont D, Muthu T, Hussain Z, Balakrishnan V: Metastasis of breast cancer to a lumbar spinal nerve root ganglion. Spine (Phila Pa 1976); 2009 Sep 15;34(20):E735-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of breast cancer to a lumbar spinal nerve root ganglion.
  • STUDY DESIGN: A case report of a surgically treated metastasis of breast cancer to the L2 nerve root ganglion.
  • OBJECTIVES: To report of an uncommon site of metastasis as the first manifestation of distant hematogenous spread of breast cancer mimicking a benign lesion.
  • To our knowledge this is the fourth reported case and the first report of a metastasis of a breast carcinoma.
  • Intraoperatively an intradural tumor was encountered and debulked.
  • The histologic examination confirmed the tumor to be a metastasis of breast cancer as determined by immunohistological staining.
  • CONCLUSION: Although very rare, metastasis to the spinal nerve root ganglion can be the first manifestation of distant hematogenous metastases of breast cancer.
  • The radiologic appearance might mimic a benign lesion.
  • Surgical intervention with tumor debulking followed by radiotherapy provides local tumor control and palliation from pain.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Ganglia, Spinal / pathology. Peripheral Nervous System Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19752693.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement